EP0126587B1 - Carboxylic thio-pyrrolidinyl beta-lactam compounds and production thereof - Google Patents
Carboxylic thio-pyrrolidinyl beta-lactam compounds and production thereof Download PDFInfo
- Publication number
- EP0126587B1 EP0126587B1 EP84303128A EP84303128A EP0126587B1 EP 0126587 B1 EP0126587 B1 EP 0126587B1 EP 84303128 A EP84303128 A EP 84303128A EP 84303128 A EP84303128 A EP 84303128A EP 0126587 B1 EP0126587 B1 EP 0126587B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- compound
- producing
- formula
- hydroxyethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 C*(C)(C)C1=C(C)CC(C2(C)*)*1(C)*2=C Chemical compound C*(C)(C)C1=C(C)CC(C2(C)*)*1(C)*2=C 0.000 description 18
- NAFOLTLUWXUQKJ-ARJAWSKDSA-N C/C=C\CCNC Chemical compound C/C=C\CCNC NAFOLTLUWXUQKJ-ARJAWSKDSA-N 0.000 description 1
- WSSDGZWSPMAECX-AKGZTFGVSA-N C1[C@@H]2NCCC12 Chemical compound C1[C@@H]2NCCC12 WSSDGZWSPMAECX-AKGZTFGVSA-N 0.000 description 1
- IBGKGKSQJWAGPO-RITPCOANSA-N CC[C@@H](C[C@@H](C)C(N)=O)S Chemical compound CC[C@@H](C[C@@H](C)C(N)=O)S IBGKGKSQJWAGPO-RITPCOANSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/20—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/88—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65611—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system (X = CH2, O, S, NH) optionally with an additional double bond and/or substituents, e.g. penicillins and analogs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- This invention relates to novel ,8-lactam compounds and a process for producing the same. More particularly, this invention relates to novel ,8-lactam compounds which are carbapenem or penem derivatives and useful as antimicrobial agents or intermediates therefor and a process for producing the same.
- JP-A-57,176,988 (C.A. 1983, 143190 w) relates to penem-3-carboxylic acid derivatives of the general formula useful a bactericides and methods for preparing them.
- EP-A-0 017 992 relates to the total synthesis of 1-carbapenem antibiotics of the general formula
- an object of the present invention is to find new carbapenem or penem derivatives which exhibit potential antimicrobial activity.
- carbapenem or penem derivatives having, as their 3-side chain, a substituent easily derived from 4-hydroxy-proline, i.e., a substituted pyrrolidinyl group carrying a carbonyl group substituted with various substituents on its 2-position, which exhibit potential antimicrobial activity and are useful as medicines or are important intermediates for compounds possessing antimicrobial activity.
- the present invention relates to novel carboxylic ,8-lactam compounds represented by the formula (I): wherein R 1 represents a 1-hydroxyethyl group or a 1-hydroxyethyl group in which the hydroxy group is protected with a protecting group; R 2 represents a hydrogen atom or a protecting group for an amino group; R 3 represents a hydrogen atom or a protecting group for a carboxyl group; X represents a substituted or unsubstituted methylene group of the formula (1): wherein R 4 represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, or X represents a sulfur atom; and Y represents a group of the formula (2): wherein R 5 and R 6 , which may be the same or different, each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 3 to 4 carbon atoms, a benzyl group, a phenethyl group, a 2-pyridylmethyl
- the protecting group for a hydroxyl group as represented by R 1 and the protecting group for an amino group as represented by R 2 may be any of those commonly employed.
- Preferred examples of these protecting groups include a lower alkoxycarbonyl group, e.g., t-butyloxycarbonyl; a halogenoalkoxycarbonyl group, e.g., 2-iodoethyloxycarbonyl or 2,2,2-trichloroethyloxycarbonyl; an aralkyloxycarbonyl group, e.g., benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl or p-nitrobenzyloxycarbonyl; and a trialkylsilyl group, e.g., trimethylsilyl or t-butyldimethylsilyl.
- the protecting group for a carboxyl group as represented by R 3 may be any of those commonly employed and preferred; examples are straight or branched chain lower alkyl groups, e.g., methyl, ethyl, isopropyl, or t-butyl; halogeno lower alkyl groups, e.g., 2-iodoethyl or 2,2,2-trichloroethyl; lower alkoxymethyl groups, e.g., methoxymethyl, ethoxymethyl or isobutoxymethyl; lower aliphatic acyloxymethyl groups, e.g., acetoxymethyl, propionyloxymethyl, butyryloxymethyl, or pivaloyloxymethyl; 1-lower alkoxycarbonyloxyethyl groups, e.g., 1-methoxycarbonyloxyethyl or 1-ethoxycarbonyloxyethyl; aralkyl groups, e.g., p-methoxybenzyl,
- the (C1-C3) alkyl group includes, for example, methyl, ethyl or n-propyl.
- R 5 and R 6 may be the same or different from each other.
- the alkyl group having 1 to 5 carbon atoms includes e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl or t-butyl
- the alkenyl group having 3 to 4 carbon atoms includes, for example, propenyl or butenyl.
- R 5 and R 6 further include a benzyl group, a phenethyl group, a 2-pyridylmethyl group, a 3-pyridylmethyl group or a 4-pyridylmethyl group; in the definition of R 5 and R 6 , the substituted alkyl group having 1 to 5 carbon atoms includes, for example, straight chain or branched chain alkyl groups, e.g., methyl, ethyl, n-propyl, isopropyl or n-butyl, which are substituted with a hydroxyl group, a di-(C i -C 3 ) alkylamino group, a carbamoyl group, a mono- or di-(C i -C 3 ) alkyl-substituted aminocarbonyl group, a protected or unprotected carboxyl group or a like substituent; and the pyridyl group includes 2-pyridyl, 3-pyridyl and 4-
- R 5 and R 6 jointly represent an alkylene chain or an alkylene chain containing an oxygen atom, a sulfur atom or a (C 1 -C 3 ) alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, a substituted or unsubstituted 3- to 7-membered cyclic amino group which may contain double bond-(s) in its ring
- the cyclic amino group includes, for example, a saturated cyclic amino group, e.g.
- the substituents for these cyclic amino groups include, for example, an alkyl group having 1 to 3 carbon atoms, a carbamoyl group, a mono- or di-(C 1 -C 3 )alkyl-substituted aminocarbonyl group or a hydroxyl group.
- R 8 is a hydrogen atom, a protecting group commonly employed for protection of a hydroxyl group or a lower alkyl group, e.g., methyl, ethyl or n-propyl.
- the carboxylic acid compounds wherein the group as represented by -COOR 3 or -COY is a carboxyl group can be converted into their pharmacologically acceptable salts, if desired.
- Such salts include those formed with inorganic metals, such as lithium, sodium, potassium, calcium or magnesium and those formed with ammonium, such as ammonium, cyclohexylammonium, diisopropylammonium or triethylammonium, with a sodium salt and a potassium salt being preferred.
- R 1 is a 1-hydroxyethyl group
- R 2 and R 3 are both hydrogen atoms
- Y is a group represented by the formula (2-a): wherein R 5 -a and R 6 -a each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 3 to 4 carbon atoms, a benzyl group, a phenethyl group, a 2-pyridylmethyl group, a 3-pyridylmethyl group or a 4-pyridylmethyl group, an alkyl group having 1 to 5 carbon atoms which is substituted with a hydroxyl group, a di-(C i -C 3 )alkylamino group, a carbamoyl group, a mono- or di-(Ci -C 3 )-alkyl-substituted aminocarbonyl group or a carboxyl group, or a pyri
- R 1 is a 1-hydroxylethyl group
- R 2 and R 3 are both hydrogen atoms
- Y is a group represented by the formula (2-b): wherein R 5 - b and R 6 - b each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 3 to 4 carbon atoms, a benzyl group, a phenethyl group, a 2-pyridylmethyl group, a 3-pyridylmethyl group or a 4-pyridylmethyl group; an alkyl group having 1 to 5 carbon atoms which is substituted with a hydroxyl group, a di-(C 1 -C 3 )alkylamino group, a carbamoyl group, a mono- or di-(C 1 -C 3 )-alkyl-substituted aminocarbonyl group or a carboxyl group, or a
- Y include a group represented by the formula: wherein R 5 - d represents a hydrogen atom or a methyl group, and R 6 - d represents a group of the formula: wherein R a , R b and R c each represents a hydrogen atom or a methyl group.
- R 1 is a 1-hydroxyethyl group
- R 2 and R 3 are both hydrogen atoms
- Y is a group represented by the formula (2-c): wherein R 5-c and R 6-c have one of the following meanings:
- Preferred examples of X can include a sulfur atom, a methyl-substituted or unsubstituted methylene group as claimed in claims 7, more preferred as represented by the formula (1-a): wherein R 4 -a represents a hydrogen atom or a methyl group, with a group being particularly preferred.
- Preferred compounds are (5R)-compounds, more preferred are (5R,6S,8R)-compounds and most preferred are (5R,6S,8R,2'S,4'S)-compounds of the formula and preferred compounds are (5R)-compounds, more preferred are (5R,6S,8R)-compounds and most preferred are (5R,6S,8R,2'S,4'S)-compounds of the formula wherein Y, R 2 and R 3 are as defined above.
- Preferred compounds are also (5S)-compounds, more preferred are (5S,6S,8R)-compounds and most preferred are (5S,6S,8R,2'S,4'S)-compounds of the formula wherein Y, R 2 and R 3 are as defined above and R 4 is an alkyl group having one to three carbon atoms.
- 5S is also preferred.
- R 8 represents a hydrogen atom, a protecting group for a hydroxyl group or an alkyl group having 1 to 3 carbon atoms, and a pharmaceutically acceptable salt thereof.
- the ,8-lactam compounds represented by the formula (I) according to the present invention are novel compounds which are carbapenem (i.e., 1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylic acid) derivatives or penem (i.e., 1-azabicyclo[3.2.0]hept-2-ene-7-one-4-thia-2-carboxylic acid derivatives.
- reactive ester group of an alcohol herein used means a group derived from a substituted or unsubstituted arylsulfonate, lower alkanesulfonate, halogeno-lower alkanesulfonate or diarylphosphoric acid ester or a halide, i.e., an ester with a hydrogen halide, of the alcohol represented by the formula (II).
- the substituted or unsubstituted arylsulfonate includes, for example, a benzenesulfonate, a p-toluenesulfonate, a p-nitrobenzenesulfonate or a p-bromobenzenesulfonate.
- the lower alkanesulfonate includes, for example, a methanesulfonate or an ethanesulfonate.
- the halogeno-lower alkanesulfonate includes, for example, a trifluouromethanesulfonate.
- the diarylphosphoric acid ester includes, for example, a diphenylphosphoric acid ester.
- the halide includes, for example, a chloride, a bromide or an iodide.
- reactive esters of an alcohol preferred examples are a p-toluenesulfonate, a methanesulfonate and a diphenylphosphoric acid ester.
- the lower alkyl group preferably includes a straight chain or branched chain alkyl group having 1 to 4 carbon atoms.
- the substituent for the substituted lower alkyl group can include a hydroxyl group, a lower alkoxy group having 1 to 4 carbon atoms, a lower alkoxycarbonyloxy group having 2 to 5 carbon atoms, a lower alkanoyloxy group having 2 to 5 carbon atoms, an amino group, a mono- or di-lower alkylamino group, a lower alkanoylamino group having 2 to 5 carbon atoms, a lower alkoxycarbonylamino group having 2 to 5 carbon atoms, an aralkyloxycarbonyloxy group or an aralkyloxycarbonylamino group.
- the protecting group for a carboxyl group as represented by Rg corresponds to the protecting group as represented by R 3 , and the same preferred groups as enumerated for R 3 can also be applied to R 9 .
- inert solvent examples include dioxane, tetrahydrofuran, dimethylformamide, dimethyl sulfoxide, acetonitrile, hexamethylphosphoramide and mixtures thereof, with acetonitrile and dimethylformamide being preferred.
- the base also used in the reaction includes various organic or inorganic bases, such as sodium carbonate, potassium carbonate, sodium hydride, potassium hydride, potassium t-butoxide, pyridine, various lutidines, 4-dimethylaminopyridine, triethylamine, diisopropylethylamine and the like, with the organic bases, e.g., diisopropylethylamine being preferred.
- organic bases e.g., diisopropylethylamine being preferred.
- the amount of the base to be used should be enough for the reaction to sufficiently proceed and usually ranges from 1 to 2 equivalents per mole of the mercaptan derivative of the formula (III).
- the mercaptan derivative (III) is used in an amount enough for the reaction to sufficiently proceed. It may be used in a large excess but usually in an amount of from 1 to 2 equivalents based on the compound of the formula (II).
- the reaction can be carried out at a temperature ranging from about -78 ° C to 60 ° C, preferably from -40 ° C to 40 ° C.
- reaction product After completion of the reaction, the reaction product can be isolated by usual organochemical means.
- the thus obtained compound represented by the formula (IV) can be subjected, if necessary, to a reaction for removal of the hydroxyl-protecting group when R 1 contains a protected hydroxyl group, a reaction for removal of the amino-protecting group, a reaction for removal of the carboxyl-protecting group Rg, a reaction for removal of the protecting group on Y', or an appropriate combination thereof, thereby to obtain the ,8-lactam compound represented by the formula (I).
- the reactions for removal of the protecting groups can be carried out by generally known methods selected depending on the type of the protecting groups.
- those compounds of the formula (IV) wherein the hydroxyl-protecting group and/or the amino-protecting group in R 2 is/are a halogenoalkoxycarbonyl group(s) or an aralkyloxycarbonyl group(s) and those compounds wherein the carboxyl-protecting group is a halogenoalkyl group, an aralkyl group or a benzhydryl group can be subjected to an appropriate reduction reaction to remove these protecting groups.
- Such reduction is preferably carried out by using an organic solvent, such as acetic acid, tetrahydrofuran or methanol and zinc in case when the protecting group to be removed is a halogenoalkoxycarbonyl group or a halogenoalkyl group, or by catalytic reduction using a catalyst, such as platinum or palladium-on-carbon, in case when the protecting group to be removed is an aralkyloxycarbonyl group, an aralkyl group or a benzhydryl group.
- an organic solvent such as acetic acid, tetrahydrofuran or methanol and zinc
- a catalyst such as platinum or palladium-on-carbon
- Solvents to be used in the catalytic reduction suitably include organic solvents, such as lower alcohols, e.g., methanol or ethanol; ethers, e.g., tetrahydrofuran or dioxane; and acetic acid, or mixed solvents of these organic solvents and water or buffer solutions, such as phosphoric acid, morpholinopropanesulfonic acid.
- organic solvents such as lower alcohols, e.g., methanol or ethanol
- ethers e.g., tetrahydrofuran or dioxane
- acetic acid or mixed solvents of these organic solvents and water or buffer solutions, such as phosphoric acid, morpholinopropanesulfonic acid.
- the reaction can be conducted at a temperature of from about 0 ° C to 100 ° C, preferably 0 ° C to 40 °C, in a hydrogen atmosphere under atmospheric pressure or under pressurized conditions.
- the protecting group to be removed is an o-nitrobenzyl group or an o-nitrobenzyloxycarbonyl group, these groups can also be removed by photo reaction.
- the 2'- and 4'-positions in the 3-side chain of the compounds of the formula (I), (V) and (VI) are all asymmetric carbons to form isomers.
- the compounds represented by these formulae include optical isomers and steric isomers ascribed to these asymmetric carbon atoms. Although all of these isomers are represented by a respective single formula for the sake of convenience, the scope of the present invention is not limited by such a single formula.
- preferred isomers can include those having the same relative-configuration as thienamycin at the 5-positioned carbon atom.
- those having an R-configuration are preferred.
- those wherein the lower alkyl group as represented by R 4 is in an R-configuration are preferred.
- the 2'-substituted pyrrolidin-4'-ylthio group forms four isomers, of which the (2'S,4'S)- and (2'R,4'R)-compounds are preferred.
- Particularly preferred compounds include those compounds of the formula (V), wherein X is a sulfur atom or a methylene group, having a (5R,6S,8R,2'S,4'S)-configuration, those compounds of the formula (V), wherein X is an alkylated methylene group having a (5S,6S,8R, 2'S,4'S)-configuration, and those compounds of the formula (VI) wherein R 1 is a 1-hydroxyethyl type substituent and R 4 is a lower alkyl group, having a (4R,5S,6S,8R,2'S,4'S)-configuration.
- the isomers having the above-described steric configurations can be obtained by using the starting compounds of the formula (II) and/or (III) having the corresponding configurations.
- the starting compounds (II) can be prepared according to various known methods.
- the compounds represented by the formula (VII): wherein R 4, R 9 and R 10 are as defined above, and Z o represents a reactive ester group of an alcohol, and also wherein R 4 is a hydrogen atom are known per se in (1) Japanese Patent Application OPI (Open to Public Inspection) No. 27169/80, (2) J. Am. Chem. Soc., Vol. 103, 6765-6767 (1981) and (3) J. Chem. Soc., Perkin I, 964-968 (1981) and the compounds (VII) can be obtained according to the methods described in the above-described literatures (1) to (3).
- the compounds (VII) can also be synthesized in accordance with the methods described in the above-described literatures (1) to (3) starting with compounds represented by the formula (a): wherein R 1 is as defined above, and Ac represents an acetyl group, which can be obtained by the method described in Tetrahedron Letters, 2293-2296 (1982) or the method described in EPC Publication No. 70204.
- the compounds (VII) can also be obtained by subjecting a compound represented by the formula (b): wherein DAM represents a di-p-anisylmethyl group, which is obtained by the method disclosed in EPC Publication No. 70204 to a carbon-increasing reaction such as Arndt-Eistert reaction or the like and then to an oxymercuration reaction or the like according to the method of EPC Publication No.
- the DAM group on the nitrogen atom in the compound (c) can be removed by reacting with ceric ammonium nitrate in an inert solvent such as acetonitrile-water at 10 to 30 ° C. In this case, this reaction may be combined with a reaction for protecting or deprotecting the carboxyl group and/or a reaction for protecting the hydroxyl group, if necessary.
- the compound of the formula (VII) wherein R 4 is an alkyl group can be prepared by, for example, the known method as disclosed in Japanese Patent Application OPI No. 26887/83 or analogous methods thereof.
- the compounds of the formulae (e) and (f) can be obtained as an isomeric mixture by a method described in Japanese Patent Application OPI No. 73656/80 which comprises reacting (3R,4R)-4-acetoxy-3-[(R)-1-(t-butyldimethylsilyloxy)ethyl]-2-azetidinone of the formula (d) disclosed in Chem. Pharm. Bull., Vol.
- a halogenofatty acid ester represented by the formula: wherein R 4 0 and R 11 are as defined above, and X' represents a halogen atom, in a solvent, such as an ether (e.g., tetrahydrofuran, dioxane or diethyl ether), an aromatic hydrocarbon (e.g., benzene or toluene), and the like, or a mixed solvent of these solvents and hexane in the presence of diethylaluminium chloride and zinc.
- a solvent such as an ether (e.g., tetrahydrofuran, dioxane or diethyl ether), an aromatic hydrocarbon (e.g., benzene or toluene), and the like, or a mixed solvent of these solvents and hexane in the presence of diethylaluminium chloride and zinc.
- the compounds (e) and (f) can be led to the compound (VIII) by appropriately combining reactions for protecting or deprotecting the hydroxyl group, the carboxyl group or the nitrogen atom.
- the compound (g) obtainable by the aforesaid methods can be led to the compound (h) through the reaction described in Japanese Patent Application OPI No. 167964/82 or Heterocycles, Vol. 14, 1305-1306 (1980).
- the compound (h) is then reacted with a diazonizing agent, e.g., carboxybenzenesulfonazide, in the presence of a base to obtain the compound (i) as disclosed in Tetrahedron Letters, 31-34 (1980).
- a diazonizing agent e.g., carboxybenzenesulfonazide
- the compound (i) is then subjected to cyclization in the presence of a metal salt catalyst, e.g., dirhodium tetrakisacetate, or to photo reaction to obtain the compound (j).
- a metal salt catalyst e.g., dirhodium tetrakisacetate
- the compound (j) is reacted with diphenyl-phosphoryl chloride in an inert solvent in the presence of a base such as diisopropyl ethyl amine or 4-dimethylaminopyridine to obtain the compound of the formula (VII-a).
- a base such as diisopropyl ethyl amine or 4-dimethylaminopyridine
- the starting compound (VII-a) as prepared from the compound (j) is subsequently subjected to the reaction with various mercaptans without being isolated to produce carbapenem derivatives, but the starting compound (VII-a) may also be once isolated from the reaction mixture and then reacted with the mercaptan derivative (III) to obtain the desired compound of the formula (IV).
- Optically active reactive esters for example, the compound (VII-a), can be obtained in the same manner as described above but starting with the ⁇ -lactam derivative (g) having the corresponding steric configuration.
- the compounds for example, of the compound (IX): wherein R 1 and Rg are as defined above, and R 12 represents a substituted or unsubstituted lower alkyl group, can be prepared by subjecting a compound of the formula (X): wherein R 1, R 9 and R 12 are as defined above, to S-oxidation using a mild oxidizing agent.
- the mild oxidizing agent includes perbenzoic acid, m-chloroperbenzoic acid, hydrogen peroxide, selenium dioxide, sodium m-periodate and the like, with substituted perbenzoic acids, e.g., m-chloroperbenzoic acid being preferred.
- the starting compound represented by the formula (X) can be prepared by various methods already reported, for example, the methods as disclosed in Japanese Patent Applications OPI Nos. 9034/80, 105686/80 and 81591/81.
- the starting mercaptan derivative of the formula (III) can be prepared by various methods.
- mercaptan derivatives (ilia), (Illb) and (Illc) having a 2'S-configuration can be obtained from trans-4-hydroxy-L-proline (i) in accordance with the reaction scheme shown below:
- Rs, R 6 and R 11 are as defined above;
- R 13 represents a protecting group for an amino group;
- R 14 represents a protecting group for a thiol group.
- the reaction can easily be accomplished by various known methods generally employed for protecting an amino group of amino acids, for example, a method comprising reacting with an arylmethyloxycarbonyl chloride in the presence of a base, a method comprising using an S-acyl-4,6-dimethyl-2-mercaptopyrimidine and the like.
- the reaction can be carried out by various methods for obtaining esters from carboxylic acids, for example, by reacting the carboxylic acid (ii) with various alkyl halides or aralkyl halides in the presence of a base.
- the reaction can be accomplished by various known methods for converting a hydroxyl group into a protected thiol group, for example, by a method comprising converting the carboxylic acid ester (iii) into an active ester of a hydroxyl group and then reacting with various thionizing reagents, e.g., thioacetic acid, thiobenzoic acid or tritylmercaptan in the presence of a base.
- various thionizing reagents e.g., thioacetic acid, thiobenzoic acid or tritylmercaptan in the presence of a base.
- This step may also be conducted by reacting the alcohol derivative with a thionizing reagent, e.g., thioacetic acid in an inert solvent, e.g., tetrahydrofuran in the presence of triphenylphosphine and diethyl azodicarboxylate.
- a thionizing reagent e.g., thioacetic acid
- an inert solvent e.g., tetrahydrofuran
- This step can be carried out by various known methods for converting an ester group into a carboxyl group, for example, alkali-hydrolysis, a method of using trifluoroacetic acid or hydrobromic acid or a reductive method of using zinc.
- the reaction can be achieved by various known methods for converting a carboxyl group to an amido group, for example, by a method comprising reaction with a halogenating agent, an acylating agent to form an active ester derivative and then treating the resulting ester with an amine represented by the formula: wherein R 5 and R 6 are as defined above.
- the thiol-protecting group can be removed by various known methods for deprotection.
- an acyl group as the thiol-protecting group can be removed by alkali-hydrolysis or the like.
- the reaction can be accomplished by various known oxidation methods for converting a hydroxyl group into a carbonyl group, for example, an oxidation reaction using chromic acid-sulfuric acid in acetone.
- the step can be conducted by various known reduction reactions for converting a carbonyl group to a hydroxyl group.
- treatment with sodium borohydride gives a mixture of the compound (iii) and the compound (ix) having different steric configurations at the hydroxyl group.
- the production proportion of (iii) and (ix) varies depending on reaction conditions, but each compound can be isolated as a single compound by purification procedures, such as recrystallization, chromatography or the like.
- the alcohol derivative is reacted with formic acid in an inert solvent, e.g., tetrahydrofuran in the presence of triphenylphosphine and diethyl azodicarboxylate to form a formyloxy derivative (xiii), which is then subjected to alkali-hydrolysis to remove the formyl group.
- an inert solvent e.g., tetrahydrofuran
- This step can be conducted by commonly employed various known methods for deprotecting amino groups, for example, a method of using an acid, e.g., trifluoroacetic acid or hydrobromic acid, a reducing method of using zinc or lithium-liquid ammonia or a catalytically reducing method.
- a method of using an acid e.g., trifluoroacetic acid or hydrobromic acid
- a reducing method of using zinc or lithium-liquid ammonia e.g., zinc or lithium-liquid ammonia or a catalytically reducing method.
- the starting mercaptan derivatives (III) to be used for the production of the ,8-lactam compounds (I) wherein Y is a protected or unprotected hydroxyl group or an alkoxy group having 1 to 3 carbon atoms can be obtained by subjecting the compound (iv) or (x) to Step F.
- the 2'R-mercaptan (III) can be prepared by using cis-4-hydroxy-D-proline as a starting compound in accordance with the above-described method for producing 2'S-compounds, i.e., by combining various reactions described in the production of the 2'S-compounds.
- novel ,8-lactam compounds represented by the formula (I) according to the present invention those compounds in which R 2 and R 3 are hydrogen atoms exhibit excellent antimicrobial activity against a wide variety of disease-causing bacteria including Gram positive bacteria, such as Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes or Streptococcus faecalis and Gram negative bacteria, such as Escherichia coli, Proteus mirabilis, Serratia marcescens or Pseudomonas aeruginosa and are useful, therefore, as antimicrobial agents. Further, these compounds have a characteristic of exhibiting excellent antimicrobial activity against ,8-lactamase-producing strains. Other compounds according to the present invention are important intermediates for synthesizing the above-mentioned compounds having antimicrobial activity.
- the compounds according to the present invention are also characterized in general by their high physiochemical stability and excellent water solubility, although varying depending on the respective compound.
- the compounds of the present invention can be used as antimicrobial agents for treating bacteria- caused infectious diseases in the form of oral preparations, such as tablets, capsules, powders or syrups or non-oral preparations, such as intravenous injections, intramuscular injections or rectal preparations.
- the dosage of the antimicrobial agent varies depending upon the symptoms, ages, body weights, dosage forms, times of doses and the like, but usually ranges from about 100 mg to 3,000 mg per day in a single dose or several divided doses for adults.
- the above dose level can be increased or decreased according to necessity.
- the antimicrobial agent of the present invention can be administered, if necessary, in combination with dehydrodipeptidase-inhibitors, e.g., sodium Z-7-(L-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropanecarboxyamido)-2-heptenoate (a series of compounds disclosed in Japanese Patent Application OPI No. 81518/81).
- dehydrodipeptidase-inhibitors e.g., sodium Z-7-(L-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropanecarboxyamido)-2-heptenoate (a series of compounds disclosed in Japanese Patent Application OPI No. 81518/81).
- the ethereal layer was washed with 20 ml of a 1 N sodium hydroxide aqueous solution and combined with the alkaline aqueous layer.
- the combined mixture was made acidic with 100 ml of a 2N hydrochloric acid aqueous solution and extracted with ethyl acetate.
- the ethyl acetate layer was washed with a 2N aqueous solution of hydrochloric acid, dried over sodium sulfate and distilled off to remove the solvent.
- the resulting crude crystals were washed with warm ethyl acetate to obtain trans-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-proline.
- the above prepared compound could also be obtained by the following method: 200 mg of the same starting carboxylic acid was dissolved in 1.8 ml of dried methylene chloride, and one drop of dimethylformamide was added thereto. 0.12 ml of oxalyl chloride was then added dropwise thereto under ice-cooling, followed by stirring at room temperature for 1 hour. The solvent was removed by distillation, and the residue was thoroughly dried in vacuo and dissolved in 1 ml of dried tetrahydrofuran. Under ice-cooling, 1.2 ml of a 1 M solution of dimethylamine in tetrahydrofuran was added to the reaction mixture, followed by stirring at that temperature for 15 minutes.
- a solution of 642 mg of thioacetic acid in 14 ml of dried dimethylformamide was added to a suspension of 374 mg of 50% sodium hydride in 13 ml of dried dimethylformamide in a nitrogen stream, followed by stirring at room temperature for 25 minutes.
- To the mixture were added 975 mg of sodium iodide and then a solution of 2.52 g of trans-1-(p-nitrobenzyloxycarbonyl)-4-methanesulfonyloxy-L-prolineamidein 12 ml of dried dimethylformamide, and the resulting mixture was heated at 70 ° C for 6 hours while stirring.
- the reaction mixture was poured into a cool aqueous solution of sodium chloride and extracted with benzene.
- the extract was washed successively with a 10% aqueous solution of sodium sulfite and a sodium chloride aqueous solution, dried over sodium sulfate and distilled off to remove the solvent.
- the resulting crude crystals were washed with a warm mixed solvent of tetrahydrofuran and benzene to obtain cis-1-(e-nitrobenzyloxycarbonyl)-4-acetylthio-L-prolineamide.
- a solution of 0.35 ml of dimethyl sulfoxide in 1 ml of dried methylene chloride was added dropwise to a solution of 0.2 ml of oxalyl chloride in 5 ml of dried methylene chloride at -60 ° to -70 ° C.
- 10 ml of a dried methylene chloride solution of 860 mg of trans-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-proline p-methoxybenzyl ester was added dropwise to the above mixture at a temperature of -50 ° C or less, followed by stirring for 15 minutes. 1.01 g of triethylamine was then added dropwise thereto, and the resulting mixture was warmed to room temperature.
- trans-1-p-nitrobenzyloxycarbonyl-4-hydroxy-L-proline-p-nitrobenzyl ester was obtained.
- reaction mixture was concentrated under reduced pressure, diluted with ethyl acetate, washed successively with an aqueous solution of sodium bicarbonate and water and dried over sodium sulfate.
- the solvent was removed by distillation, and the residue was subjected to silica gel thin layer chromatography to obtain (2S,4S)-2-benzylcarbamoyl-4-acetylthiopyrrolidine. 3325,1690,1510,1400,1350,1120,950
- reaction mixture was diluted with ethyl acetate and diethyl ether, washed successively with dilute hydrochloric acid and water, dried over sodium sulfate and distilled off to remove the solvent thereby obtaining 1-(di-p-anisylmethyl)-3- ethenyl-4-p-methoxybenzyloxycarbonylmethyl-2-azetidinone.
- the concentrate was diluted with cool water and ethyl acetate, washed successively with a 1 N aqueous solution of hydrochloric acid and water, dried over sodium sulfate and distilled off to remove the solvent.
- the resulting residue was purified by silica gel chromatography to obtain 1-(di-p-anisylmethyl)-3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-[3-t-butoxycarbonyl-3-(p-nitrobenzyloxycarbonyl)-2- oxopropyl]-2-azetidinone. 1750, 1610, 1510, 1345, 1250
- the isomeric mixture was separated into each compound by Lober column chromatography using silica gel and 1.5% isopropanol/n-hexane as an eluent to obtain the compound (2a) and the compound (2b) as oily substances.
- reaction mixture was diluted with ethyl acetate, washed with water, dried over sodium sulfate and purified by silica gel chromatography to obtain 4-(1-benzyloxycarbonyl)-ethyl-3-[(R)-1-(t-butyl- dimethylsilyloxy)-ethyl]-1-(t-butyldimethylsilyl)-2-azetidinone (3a). 1750,1465,1325,1255,835
- reaction solution was diluted with ethyl acetate, washed with water, dried over magnesium sulfate and the solvent was distilled off.
- residue was purified by silica gel thin layer chromatography to obtain 35 mg of (4R,5S,6S, 8R,2'S,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl)-pyrrolidinylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0] hept-2-ene-7-one-2-carboxylate. 1760, 1705, 1645, 1520, 1402, 1342, 1135, 1110
Abstract
Description
- This invention relates to novel ,8-lactam compounds and a process for producing the same. More particularly, this invention relates to novel ,8-lactam compounds which are carbapenem or penem derivatives and useful as antimicrobial agents or intermediates therefor and a process for producing the same.
- Since the discovery of thienamycin having a potential antimicrobial activity against Gram negative and Gram positive bacteria, studies on synthesis of carbapenem or penem derivatives which are analogous to thienamycin have been widely developed.
-
-
-
- Therefore, an object of the present invention is to find new carbapenem or penem derivatives which exhibit potential antimicrobial activity.
- This object has been solved by carbapenem or penem derivatives having, as their 3-side chain, a substituent easily derived from 4-hydroxy-proline, i.e., a substituted pyrrolidinyl group carrying a carbonyl group substituted with various substituents on its 2-position, which exhibit potential antimicrobial activity and are useful as medicines or are important intermediates for compounds possessing antimicrobial activity.
- The present invention relates to novel carboxylic ,8-lactam compounds represented by the formula (I):
- In the above-described formula (I), the protecting group for a hydroxyl group as represented by R1 and the protecting group for an amino group as represented by R2 may be any of those commonly employed. Preferred examples of these protecting groups include a lower alkoxycarbonyl group, e.g., t-butyloxycarbonyl; a halogenoalkoxycarbonyl group, e.g., 2-iodoethyloxycarbonyl or 2,2,2-trichloroethyloxycarbonyl; an aralkyloxycarbonyl group, e.g., benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl or p-nitrobenzyloxycarbonyl; and a trialkylsilyl group, e.g., trimethylsilyl or t-butyldimethylsilyl.
- The protecting group for a carboxyl group as represented by R3 may be any of those commonly employed and preferred; examples are straight or branched chain lower alkyl groups, e.g., methyl, ethyl, isopropyl, or t-butyl; halogeno lower alkyl groups, e.g., 2-iodoethyl or 2,2,2-trichloroethyl; lower alkoxymethyl groups, e.g., methoxymethyl, ethoxymethyl or isobutoxymethyl; lower aliphatic acyloxymethyl groups, e.g., acetoxymethyl, propionyloxymethyl, butyryloxymethyl, or pivaloyloxymethyl; 1-lower alkoxycarbonyloxyethyl groups, e.g., 1-methoxycarbonyloxyethyl or 1-ethoxycarbonyloxyethyl; aralkyl groups, e.g., p-methoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, a benzhydryl group and a phthalidyl group.
- When X is a (C1-C3)alkyl-substituted or unsubstituted methylene group as represented by the formula (1), the (C1-C3) alkyl group includes, for example, methyl, ethyl or n-propyl.
- When Y is an amino group represented by the formula (2), R5 and R6 may be the same or different from each other. In the definition of R5 and R6, the alkyl group having 1 to 5 carbon atoms includes e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl or t-butyl, the alkenyl group having 3 to 4 carbon atoms includes, for example, propenyl or butenyl. R5 and R6 further include a benzyl group, a phenethyl group, a 2-pyridylmethyl group, a 3-pyridylmethyl group or a 4-pyridylmethyl group; in the definition of R5 and R6, the substituted alkyl group having 1 to 5 carbon atoms includes, for example, straight chain or branched chain alkyl groups, e.g., methyl, ethyl, n-propyl, isopropyl or n-butyl, which are substituted with a hydroxyl group, a di-(Ci-C3) alkylamino group, a carbamoyl group, a mono- or di-(Ci-C3) alkyl-substituted aminocarbonyl group, a protected or unprotected carboxyl group or a like substituent; and the pyridyl group includes 2-pyridyl, 3-pyridyl and 4-pyridyl groups.
- In cases where R5 and R6 jointly represent an alkylene chain or an alkylene chain containing an oxygen atom, a sulfur atom or a (C1-C3) alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, a substituted or unsubstituted 3- to 7-membered cyclic amino group which may contain double bond-(s) in its ring, the cyclic amino group includes, for example, a saturated cyclic amino group, e.g. an azirodino group, an azetidino group, a pyrrolidino group or a piperidino group; an unsaturated cyclic amino group, e.g., a pyrrolyl group or a 3-pyrrolinyl group; and a cyclic amino group having an oxygen atom, a sulfur atom or an alkyl-substituted nitrogen atom in its ring, e.g., a morpholino group, a thiomorpholino group or an N-methylpiperazino group. The substituents for these cyclic amino groups include, for example, an alkyl group having 1 to 3 carbon atoms, a carbamoyl group, a mono- or di-(C1-C3)alkyl-substituted aminocarbonyl group or a hydroxyl group.
- In cases where Y is represented by the formula (4), R8 is a hydrogen atom, a protecting group commonly employed for protection of a hydroxyl group or a lower alkyl group, e.g., methyl, ethyl or n-propyl.
- Of the compounds of the above-described formula (I), the carboxylic acid compounds wherein the group as represented by -COOR3 or -COY is a carboxyl group can be converted into their pharmacologically acceptable salts, if desired. Such salts include those formed with inorganic metals, such as lithium, sodium, potassium, calcium or magnesium and those formed with ammonium, such as ammonium, cyclohexylammonium, diisopropylammonium or triethylammonium, with a sodium salt and a potassium salt being preferred.
- The preferred compounds of the formula (I) are those wherein R1 is a 1-hydroxyethyl group; R2 and R3 are both hydrogen atoms; and Y is a group represented by the formula (2-a):
- The more preferred compounds of the formula (I) are those wherein R1 is a 1-hydroxylethyl group; R2 and R3 are both hydrogen atoms, and Y is a group represented by the formula (2-b):
-
-
-
- (1) R5-crepresents an alkyl group having 1 to 5 carbon atoms which may be substituted with a carbamoyl group, a mono- or di-(C1-C3)alkylaminocarbonyl group or a hydroxyl group, or a pyridyl group, and R6-c represents a hydrogen atom or has the same meaning as described for R5-c;
- (2) R5-c and R6-c are directly taken together to represent an alkylene chain to form, together with the adjacent nitrogen atom, a 4- to 6-membered saturated cyclic amino group or a 5 to 6-membered unsaturated cyclic amino group having double bond(s) in its ring, such as a pyrrolinyl group, or the same saturated or unsaturated cyclic amino group as described above but having a substituent on its ring, such as a carbamoyl group or a hydroxyl group, and
- (3) R5-c and R6-c jointly represent an alkylene chain containing an oxygen atom or a (C1-C3)alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, a 6-membered cyclic amino group.
- Preferred examples of X, if positively enumerated, can include a sulfur atom, a methyl-substituted or unsubstituted methylene group as claimed in claims 7, more preferred as represented by the formula (1-a):
- Preferred compounds are (5R)-compounds, more preferred are (5R,6S,8R)-compounds and most preferred are (5R,6S,8R,2'S,4'S)-compounds of the formula
-
- 1.*) (5R)-3-[2-(Dimethylaminocarbonyl)pyrrolidin-4-ylthio-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-4-thia-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 2.*) (5R)-3-[2-((1-Pyrrolidino)carbonyl)pyrrolidin-4-ylthio-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-4-thia-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 3.*) (5R)-3-[2-Carbamoylpyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-4-thia-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 4.*) (5R)-3-[2-(Dimethylaminocarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2- ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 5.*) (5R)-3-[2-((1-Pyrrolidino)carbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 6.*) (5R)-3-[2-((1-Pyrrolin-3-yl)carbonyl)pyrrolidin-4-ylthio]-6-(l -hydroxyethyl)-1-azabicyclo[3.2.0]hept-2- ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 7.*) (5R)-3-[2-((1-Azetidino)carbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 8.*) (5R)-3-[2-((3-Hydroxy-1-pyrrolidino)carbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]-hept-2-ene-7-one-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 9.*) (5R)-3-[2-((2-Hydroxyethyl)methylaminocarbonyl)pyrroldin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo-[3.2.0]hept-3-ene-7-one-2-carboxylic acid, or a non-toxic pnarmaceutically acceptable salt thereof;
- 10.*) (5R)-3-[2-(1-Morpholinocarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2- ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 11.*) (5R)-3-[2-(1-N-Methylpiperazinocarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]-hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 12.*) (5R)-3-[2-Carbamoylpyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 13.*) (5R)-3-[2-(4-Pyridylaminocarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2- ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 14.*) (5S)-3-[2-(Dimethylaminocarbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo-[3.2.0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 15.*) (5S)-3-[2-((1-pyrrolidino)carbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]-hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 16.*) (5S)-3-[2-((l1-Pyrrolin-3-yl)carbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo-[3.2.0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 17.*) (5S)-3-[2-((1-Azatidino)carbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]-hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 18.*) (5S)-3-[2-((3-Hydroxy-1-pyrrolidino)carbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 19.*) (5S)-3-[2-((2-Hydroxyethyl)methylaminocarbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 20.*) (5S)-3-[2-(1-Morpholinocarbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]-hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 21.*) (5S)-3-[2-(1-N-Methylpiperazinocarbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof;
- 22.*) (5S)-3-[2-Carbamoylpyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7- one-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.
- The compounds 1* to 13* with (5R,6S,8R)-configuration are more and with (5R,6S,8R,2'S,4'S)-configuration are most preferred. Also the compounds 14* to 22* with (5S,6S,8R)-configuration are more and with (5S,6S,8R,2'S,4'S)-configuration are most preferred. Furthermore, subject matter of the present application are the following β-lactam compounds:
- . A β-lactam compound of the formula:
- . A ,8-lactam compound represented by the formula:
- wherein R8 represents a hydrogen atom, a protecting group for a hydroxyl group or an alkyl group having 1 to 3 carbon atoms, and a pharmaceutically acceptable salt thereof.
- The ,8-lactam compounds represented by the formula (I) according to the present invention are novel compounds which are carbapenem (i.e., 1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylic acid) derivatives or penem (i.e., 1-azabicyclo[3.2.0]hept-2-ene-7-one-4-thia-2-carboxylic acid derivatives.
- A process for producing the compounds of the formula (I) according to the present invention will be described below.
- Of the β-lactam compounds of the formula (I), compounds represented by the formula (IV):
- The term "reactive ester group of an alcohol" herein used means a group derived from a substituted or unsubstituted arylsulfonate, lower alkanesulfonate, halogeno-lower alkanesulfonate or diarylphosphoric acid ester or a halide, i.e., an ester with a hydrogen halide, of the alcohol represented by the formula (II). The substituted or unsubstituted arylsulfonate includes, for example, a benzenesulfonate, a p-toluenesulfonate, a p-nitrobenzenesulfonate or a p-bromobenzenesulfonate. The lower alkanesulfonate includes, for example, a methanesulfonate or an ethanesulfonate. The halogeno-lower alkanesulfonate includes, for example, a trifluouromethanesulfonate. The diarylphosphoric acid ester includes, for example, a diphenylphosphoric acid ester. The halide includes, for example, a chloride, a bromide or an iodide. Of these reactive esters of an alcohol, preferred examples are a p-toluenesulfonate, a methanesulfonate and a diphenylphosphoric acid ester.
- Further, in the substituted or unsubstituted lower alkylsulfinyl group, the lower alkyl group preferably includes a straight chain or branched chain alkyl group having 1 to 4 carbon atoms. The substituent for the substituted lower alkyl group can include a hydroxyl group, a lower alkoxy group having 1 to 4 carbon atoms, a lower alkoxycarbonyloxy group having 2 to 5 carbon atoms, a lower alkanoyloxy group having 2 to 5 carbon atoms, an amino group, a mono- or di-lower alkylamino group, a lower alkanoylamino group having 2 to 5 carbon atoms, a lower alkoxycarbonylamino group having 2 to 5 carbon atoms, an aralkyloxycarbonyloxy group or an aralkyloxycarbonylamino group.
- The protecting group for a carboxyl group as represented by Rg corresponds to the protecting group as represented by R3, and the same preferred groups as enumerated for R3 can also be applied to R9.
- Examples of the inert solvent which can be used in the above-described reaction are dioxane, tetrahydrofuran, dimethylformamide, dimethyl sulfoxide, acetonitrile, hexamethylphosphoramide and mixtures thereof, with acetonitrile and dimethylformamide being preferred.
- The base also used in the reaction includes various organic or inorganic bases, such as sodium carbonate, potassium carbonate, sodium hydride, potassium hydride, potassium t-butoxide, pyridine, various lutidines, 4-dimethylaminopyridine, triethylamine, diisopropylethylamine and the like, with the organic bases, e.g., diisopropylethylamine being preferred.
- The amount of the base to be used should be enough for the reaction to sufficiently proceed and usually ranges from 1 to 2 equivalents per mole of the mercaptan derivative of the formula (III).
- The mercaptan derivative (III) is used in an amount enough for the reaction to sufficiently proceed. It may be used in a large excess but usually in an amount of from 1 to 2 equivalents based on the compound of the formula (II).
- The reaction can be carried out at a temperature ranging from about -78 ° C to 60 ° C, preferably from -40 ° C to 40 ° C.
- After completion of the reaction, the reaction product can be isolated by usual organochemical means.
- Then, the thus obtained compound represented by the formula (IV) can be subjected, if necessary, to a reaction for removal of the hydroxyl-protecting group when R1 contains a protected hydroxyl group, a reaction for removal of the amino-protecting group, a reaction for removal of the carboxyl-protecting group Rg, a reaction for removal of the protecting group on Y', or an appropriate combination thereof, thereby to obtain the ,8-lactam compound represented by the formula (I).
- The reactions for removal of the protecting groups can be carried out by generally known methods selected depending on the type of the protecting groups. For example, those compounds of the formula (IV) wherein the hydroxyl-protecting group and/or the amino-protecting group in R2 is/are a halogenoalkoxycarbonyl group(s) or an aralkyloxycarbonyl group(s), and those compounds wherein the carboxyl-protecting group is a halogenoalkyl group, an aralkyl group or a benzhydryl group can be subjected to an appropriate reduction reaction to remove these protecting groups. Such reduction is preferably carried out by using an organic solvent, such as acetic acid, tetrahydrofuran or methanol and zinc in case when the protecting group to be removed is a halogenoalkoxycarbonyl group or a halogenoalkyl group, or by catalytic reduction using a catalyst, such as platinum or palladium-on-carbon, in case when the protecting group to be removed is an aralkyloxycarbonyl group, an aralkyl group or a benzhydryl group. Solvents to be used in the catalytic reduction suitably include organic solvents, such as lower alcohols, e.g., methanol or ethanol; ethers, e.g., tetrahydrofuran or dioxane; and acetic acid, or mixed solvents of these organic solvents and water or buffer solutions, such as phosphoric acid, morpholinopropanesulfonic acid. The reaction can be conducted at a temperature of from about 0 ° C to 100 ° C, preferably 0 ° C to 40 °C, in a hydrogen atmosphere under atmospheric pressure or under pressurized conditions.
- In particular, when the protecting group to be removed is an o-nitrobenzyl group or an o-nitrobenzyloxycarbonyl group, these groups can also be removed by photo reaction.
- In the compounds according to the present invention, the 5- and 6-positions of the compounds of the above-described formula (I), the 8-position of the compounds represented by the formula (V):
- However, preferred isomers can include those having the same relative-configuration as thienamycin at the 5-positioned carbon atom. With respect to the 8-positioned carbon atom of the formula (V), those having an R-configuration are preferred. Further, with respect to the 4-position of the formula (VI), those wherein the lower alkyl group as represented by R4 is in an R-configuration (i.e., (4R)-compounds) are preferred.
- In addition, the 2'-substituted pyrrolidin-4'-ylthio group forms four isomers, of which the (2'S,4'S)- and (2'R,4'R)-compounds are preferred.
- Particularly preferred compounds include those compounds of the formula (V), wherein X is a sulfur atom or a methylene group, having a (5R,6S,8R,2'S,4'S)-configuration, those compounds of the formula (V), wherein X is an alkylated methylene group having a (5S,6S,8R, 2'S,4'S)-configuration, and those compounds of the formula (VI) wherein R1 is a 1-hydroxyethyl type substituent and R4 is a lower alkyl group, having a (4R,5S,6S,8R,2'S,4'S)-configuration.
- The isomers having the above-described steric configurations can be obtained by using the starting compounds of the formula (II) and/or (III) having the corresponding configurations.
- The starting compounds (II) can be prepared according to various known methods. For example, the compounds represented by the formula (VII):
- Further, the compounds (VII) can also be synthesized in accordance with the methods described in the above-described literatures (1) to (3) starting with compounds represented by the formula (a):
- Furthermore, the compounds (VII) can also be obtained by subjecting a compound represented by the formula (b):
- The DAM group on the nitrogen atom in the compound (c) can be removed by reacting with ceric ammonium nitrate in an inert solvent such as acetonitrile-water at 10 to 30 ° C. In this case, this reaction may be combined with a reaction for protecting or deprotecting the carboxyl group and/or a reaction for protecting the hydroxyl group, if necessary.
- Further, the compound of the formula (VII) wherein R4 is an alkyl group can be prepared by, for example, the known method as disclosed in Japanese Patent Application OPI No. 26887/83 or analogous methods thereof.
- Compounds of the formula (VIII):
- The compounds of the formulae (e) and (f) can be obtained as an isomeric mixture by a method described in Japanese Patent Application OPI No. 73656/80 which comprises reacting (3R,4R)-4-acetoxy-3-[(R)-1-(t-butyldimethylsilyloxy)ethyl]-2-azetidinone of the formula (d) disclosed in Chem. Pharm. Bull., Vol. 29, 2899-2909 (1981) with a halogenofatty acid ester represented by the formula:
- Separation and purification of the isomers (e) and (f) can be carried out by silica gel column chromatography.
- The compounds (e) and (f) can be led to the compound (VIII) by appropriately combining reactions for protecting or deprotecting the hydroxyl group, the carboxyl group or the nitrogen atom.
-
- More specifically, the compound (g) obtainable by the aforesaid methods can be led to the compound (h) through the reaction described in Japanese Patent Application OPI No. 167964/82 or Heterocycles, Vol. 14, 1305-1306 (1980).
- The compound (h) is then reacted with a diazonizing agent, e.g., carboxybenzenesulfonazide, in the presence of a base to obtain the compound (i) as disclosed in Tetrahedron Letters, 31-34 (1980).
- The compound (i) is then subjected to cyclization in the presence of a metal salt catalyst, e.g., dirhodium tetrakisacetate, or to photo reaction to obtain the compound (j).
- Finally, the compound (j) is reacted with diphenyl-phosphoryl chloride in an inert solvent in the presence of a base such as diisopropyl ethyl amine or 4-dimethylaminopyridine to obtain the compound of the formula (VII-a).
- In general, the starting compound (VII-a) as prepared from the compound (j) is subsequently subjected to the reaction with various mercaptans without being isolated to produce carbapenem derivatives, but the starting compound (VII-a) may also be once isolated from the reaction mixture and then reacted with the mercaptan derivative (III) to obtain the desired compound of the formula (IV).
- Optically active reactive esters, for example, the compound (VII-a), can be obtained in the same manner as described above but starting with the β-lactam derivative (g) having the corresponding steric configuration.
- Further, of the above-described compounds of the formula (II), the compounds, for example, of the compound (IX):
- The starting compound represented by the formula (X) can be prepared by various methods already reported, for example, the methods as disclosed in Japanese Patent Applications OPI Nos. 9034/80, 105686/80 and 81591/81.
- On the other hand, the starting mercaptan derivative of the formula (III) can be prepared by various methods. For example, mercaptan derivatives (ilia), (Illb) and (Illc) having a 2'S-configuration can be obtained from trans-4-hydroxy-L-proline (i) in accordance with the reaction scheme shown below:
- The reaction can easily be accomplished by various known methods generally employed for protecting an amino group of amino acids, for example, a method comprising reacting with an arylmethyloxycarbonyl chloride in the presence of a base, a method comprising using an S-acyl-4,6-dimethyl-2-mercaptopyrimidine and the like.
- The reaction can be carried out by various methods for obtaining esters from carboxylic acids, for example, by reacting the carboxylic acid (ii) with various alkyl halides or aralkyl halides in the presence of a base.
- The reaction can be accomplished by various known methods for converting a hydroxyl group into a protected thiol group, for example, by a method comprising converting the carboxylic acid ester (iii) into an active ester of a hydroxyl group and then reacting with various thionizing reagents, e.g., thioacetic acid, thiobenzoic acid or tritylmercaptan in the presence of a base.
- This step may also be conducted by reacting the alcohol derivative with a thionizing reagent, e.g., thioacetic acid in an inert solvent, e.g., tetrahydrofuran in the presence of triphenylphosphine and diethyl azodicarboxylate.
- This step can be carried out by various known methods for converting an ester group into a carboxyl group, for example, alkali-hydrolysis, a method of using trifluoroacetic acid or hydrobromic acid or a reductive method of using zinc.
- The reaction can be achieved by various known methods for converting a carboxyl group to an amido group, for example, by a method comprising reaction with a halogenating agent, an acylating agent to form an active ester derivative and then treating the resulting ester with an amine represented by the formula:
- The thiol-protecting group can be removed by various known methods for deprotection. For example, an acyl group as the thiol-protecting group can be removed by alkali-hydrolysis or the like.
- The reaction can be accomplished by various known oxidation methods for converting a hydroxyl group into a carbonyl group, for example, an oxidation reaction using chromic acid-sulfuric acid in acetone.
- The step can be conducted by various known reduction reactions for converting a carbonyl group to a hydroxyl group. For example, treatment with sodium borohydride gives a mixture of the compound (iii) and the compound (ix) having different steric configurations at the hydroxyl group. The production proportion of (iii) and (ix) varies depending on reaction conditions, but each compound can be isolated as a single compound by purification procedures, such as recrystallization, chromatography or the like.
- Isomerization of the 4-hydroxyl group can be accomplished through the above-described steps G and H, and may also be achieved through hereinafter described steps I and J.
- The alcohol derivative is reacted with formic acid in an inert solvent, e.g., tetrahydrofuran in the presence of triphenylphosphine and diethyl azodicarboxylate to form a formyloxy derivative (xiii), which is then subjected to alkali-hydrolysis to remove the formyl group.
- This step can be conducted by commonly employed various known methods for deprotecting amino groups, for example, a method of using an acid, e.g., trifluoroacetic acid or hydrobromic acid, a reducing method of using zinc or lithium-liquid ammonia or a catalytically reducing method.
- The starting mercaptan derivatives (III) to be used for the production of the ,8-lactam compounds (I) wherein Y is a protected or unprotected hydroxyl group or an alkoxy group having 1 to 3 carbon atoms can be obtained by subjecting the compound (iv) or (x) to Step F.
- The 2'R-mercaptan (III) can be prepared by using cis-4-hydroxy-D-proline as a starting compound in accordance with the above-described method for producing 2'S-compounds, i.e., by combining various reactions described in the production of the 2'S-compounds.
- Of the novel ,8-lactam compounds represented by the formula (I) according to the present invention, those compounds in which R2 and R3 are hydrogen atoms exhibit excellent antimicrobial activity against a wide variety of disease-causing bacteria including Gram positive bacteria, such as Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes or Streptococcus faecalis and Gram negative bacteria, such as Escherichia coli, Proteus mirabilis, Serratia marcescens or Pseudomonas aeruginosa and are useful, therefore, as antimicrobial agents. Further, these compounds have a characteristic of exhibiting excellent antimicrobial activity against ,8-lactamase-producing strains. Other compounds according to the present invention are important intermediates for synthesizing the above-mentioned compounds having antimicrobial activity.
- In addition, the compounds according to the present invention are also characterized in general by their high physiochemical stability and excellent water solubility, although varying depending on the respective compound.
- The compounds of the present invention can be used as antimicrobial agents for treating bacteria- caused infectious diseases in the form of oral preparations, such as tablets, capsules, powders or syrups or non-oral preparations, such as intravenous injections, intramuscular injections or rectal preparations.
- The dosage of the antimicrobial agent varies depending upon the symptoms, ages, body weights, dosage forms, times of doses and the like, but usually ranges from about 100 mg to 3,000 mg per day in a single dose or several divided doses for adults. The above dose level can be increased or decreased according to necessity.
- Besides, the antimicrobial agent of the present invention can be administered, if necessary, in combination with dehydrodipeptidase-inhibitors, e.g., sodium Z-7-(L-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropanecarboxyamido)-2-heptenoate (a series of compounds disclosed in Japanese Patent Application OPI No. 81518/81).
- The present invention will now be illustrated in greater detail with reference to the following Reference Examples and Examples, which are given only for illustration.
- "Nujol" is a paraffinic solvent.
- In Reference Examples and Examples, the following abbreviations are used:
- DAM: Di-(p-anisyl)methyl group
- TBDMS: t-Butyldimethylsilyl group
- PNZ: p-Nitrobenzyloxycarbonyl group
- PMZ: p-Methoxybenzyloxycarbonyl group
- PMB: p-Methoxybenzyl group
- PNB: p-Nitrobenzyl group
- Ph : Phenyl group
- Ac : Acetyl group
- Ms : Methanesulfonyl group
- tBu: t-Butyl group
- Me : Methyl group
- Et : Ethyl group Reference Example 1-1
- 6.55 g of trans-4-hydroxy-L-proline and 7.5 ml of triethylamine were dissolved in 15 ml of water, and a solution of 15.95 g of S-p-nitrobenzyloxycarbonyl-4,6-dimethyl-2-mercaptopyrimidine in 35 ml of dioxane was added thereto dropwise. The resulting mixture was stirred at room temperature for 1.5 hours and allowed to stand overnight. To the reaction mixture was added 30 ml of a 2N sodium hydroxide aqueous solution under ice-cooling, and the resulting mixture was extracted with diethyl ether. The ethereal layer was washed with 20 ml of a 1 N sodium hydroxide aqueous solution and combined with the alkaline aqueous layer. The combined mixture was made acidic with 100 ml of a 2N hydrochloric acid aqueous solution and extracted with ethyl acetate. The ethyl acetate layer was washed with a 2N aqueous solution of hydrochloric acid, dried over sodium sulfate and distilled off to remove the solvent. The resulting crude crystals were washed with warm ethyl acetate to obtain trans-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-proline.
-
-
-
-
- NMR δ (CDCI): 2.31 (3H, s), 3.79 (3H, s), 5.10 (2H, s), 5.24 (2H, s), 7.49 (2H, d, J=9.0Hz), 8.18 (2H, d, J = 9.OHz)ppm
-
-
-
- The above prepared compound could also be obtained by the following method: 200 mg of the same starting carboxylic acid was dissolved in 1.8 ml of dried methylene chloride, and one drop of dimethylformamide was added thereto. 0.12 ml of oxalyl chloride was then added dropwise thereto under ice-cooling, followed by stirring at room temperature for 1 hour. The solvent was removed by distillation, and the residue was thoroughly dried in vacuo and dissolved in 1 ml of dried tetrahydrofuran. Under ice-cooling, 1.2 ml of a 1 M solution of dimethylamine in tetrahydrofuran was added to the reaction mixture, followed by stirring at that temperature for 15 minutes. To the reaction mixture was added ice- water, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with dilute hydrochloric acid and water, dried over sodium sulfate and distilled off to remove the solvent.
-
-
- NMR δ (CDCI3): 2.33 (3H, s), 5.23 (2H, s), 6.35 (2H, d, J=2Hz), 7.51 (2H, d, J = 9Hz) ppm
-
-
- 40 mg of (2S,4S)-1-(p-nitrobenzyloxycarbonyl)-2-dimethylcarbamoyl-4-acetylthiopyrrolidine was dissolved in 4 ml of methanol, and 0.1 ml of a 1 N sodium hydroxide aqueous solution was added thereto, followed by stirring at room temperature for 15 minutes. 0.11 ml of a 1 N hydrochloric acid aqueous solution was then added thereto, followed by concentration under reduced pressure. The concentrate was diluted with ethyl acetate, washed with water, dried over sodium sulfate and distilled off to remove the solvent to obtain (2S,4S)-1-(p-nitrobenzyloxycarbonyl)-2-dimethylcarbamoyl-4-mercaptopyrrolidine.
- NMR δ (CDCI3): 1.90 (1H, d, J=8Hz), 2.97 (3H, s), 3.08 (3H, s), 5.19 (2H, s), 7.48 (2H, d, J=9Hz), 8.15 (2H, d, J=9Hz) ppm
-
-
- 3.10 g of trans-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-proline and 1.10 g of triethylamine were dissolved in 40 ml of dried tetrahydrofuran, and a solution of 1.20 g of ethyl chloroformate in 10 ml of dried tetrahydrofuran was added dropwise thereto at -25 ° C to -35 ° C. After stirring at the same temperature for 50 minutes, 10 ml of concentrated aqueous ammonia was added dropwise to the mixture at -25 ° to -40 ° C. The temperature was then gradually elevated to room temperature, and the reaction mixture was stirred for 1 hour, followed by concentration under reduced pressure. To the residue were added 20 ml of water and 50 ml of diethyl ether. After ice-cooling, the thus formed white crystals were separated by filtration, washed successively with cool water and cool diethyl ether, and dried under reduced pressure to yield trans-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-prolineamide. Melting Point : 163.3-164.0 ° C
-
-
-
-
-
-
-
- A solution of 0.35 ml of dimethyl sulfoxide in 1 ml of dried methylene chloride was added dropwise to a solution of 0.2 ml of oxalyl chloride in 5 ml of dried methylene chloride at -60 ° to -70 ° C. Ten minutes later, 10 ml of a dried methylene chloride solution of 860 mg of trans-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-proline p-methoxybenzyl ester was added dropwise to the above mixture at a temperature of -50 ° C or less, followed by stirring for 15 minutes. 1.01 g of triethylamine was then added dropwise thereto, and the resulting mixture was warmed to room temperature. The mixture was diluted with methylene chloride, washed with dilute hydrochloric acid aqueous solution and dried over sodium sulfate. The solvent was removed by distillation, and the residue was purified by silica gel column chromatography to yield 1-(p-nitrobenzyloxycarbonyl)-4-oxo-L-proline-p-methoxybenzyl ester.
- NMR δ (CDCI3): 3.78 (3H, s), 3.95 (2H, s), 5.08 (2H, s), 6.85 (2H, d, J = 9Hz), 8.12 (2H, d, J = 9Hz) ppm
-
- Trans-compound: The IR and NMR data were consistent with those obtained for the compound of Reference Example 1-2.
-
-
- In the same manner as described in Reference Examples 1-3 and 1-4 but using 610 mg of cis-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-proline-p-methoxybenzyl ester, trans-1-(p-nitrobenzyloxycarbonyl)-4- acetylthio-L-proline was obtained.
-
- a) In the same manner as described in Reference Example 1-5 but using 180 mg of trans-1-(p-nitrobenzyloxycarbonyl)-4-acetylthio-L-proline, 100 mg of (2S,4R)-1-(p-nitrobenzyloxycarbonyl)-2-dimethylcarbamoyl-4-acetylthiopyrrolidine was obtained.
- b) In the same manner as described in Reference Example 1-8 but using 80 mg of the thioacetate derivative prepared as in a) above, (2S,4R)-1-(p-nitrobenzyloxycarbonyl)-2-dimethylcarbamoyl-4-mercaptopyrrolidine was obtained.
- NMR 6 (CDCI3): 1.77 (1H, d, J=7Hz), 2.97 (3H, s), 3.16 (3H, s), 5.22 (2H, s), 8.16 (2H, d, J=8.5Hz) ppm
-
- 166 mg of cis-1-p-nitrobenzyloxycarbonyl-4-hydroxy-D-proline-p-methoxybenzyl ester, which was obtained from cis-4-hydroxy-D-proline in the same manner as in Reference Examples 1-1 and 1-2, and 202 mg of triphenylphosphine were dissolved in 1.5 ml of dried tetrahydrofuran, and 27 mg of formic acid was added to the solution. 134 mg of diethyl azodicarboxylate further added thereto at room temperature in a nitrogen stream. After stirring for 30 minutes, the solvent was removed by distillation. The residue was purified by silica gel chromatography to obtain trans-1-p-nitrobenzyloxycarbonyl-4-formyloxy-D-proline-p-methoxybenzyl ester.
- NMR 6 (CDCI3): 3.76 (3H, s), 4.50 (2H, t, J = 8Hz), 5.08 (2H, s), 5.15 (2H, ABq., J=16Hz), 5.41 (1 H, m), 7.97 (1 H, s) ppm
-
- NMR δ (CDCI3): 2.33 (2H, m), 3.58 (2H, d, J=3.5Hz), 3.73 (3H, s), 5.03 (2H, s), 5.07 (2H, ABq., J = 18Hz), 6.73 (2H, d, J = 9Hz), 6.77 (2H, d, J = 9Hz), 8.00 (2H, d, J = 8.5Hz), 8.07 (2H, d, J = 8.5Hz)ppm
-
- a) In the same manner as described in Reference Examples 1-3, 1-4 and 1-5 but using 110 mg of trans-1-p-nitrobenzyloxycarbonyl-4-hydroxy-D-proline-p-methoxybenzyl ester, (2R,4R)-1-p-nitrobenzyloxycarbonyl-2-dimethylcarbamoyl-4-acetylthiopyrrolidine was obtained.
- b) In the same manner as described in Reference Example 1-8 but using 42 mg of the thioacetate derivatve as obtained in a) above, (2R,4R)-1-p-nitrobenzyloxycarbonyl-2-dimethylcarbamoyl-4-mercaptopyrrolidine was obtained.
-
- a) In the same manner as described in Reference Examples 1-3, 1-4 and 2-1 but using 110 mg of trans-1-p-nitrobenzyloxycarbony-4-hydroxy-D-proline-p-methoxybenzyl ester, 40 mg of (2R,4R)-1-p-nitrobenzyloxycarbonyl-2-carbamoyl-4-acetylthiopyrrolidine was obtained.
- b) In the same manner as described in Reference Example 1-8 but using 40 mg of the thioacetate derivative as obtained in a) above, (2R,4R)-1-p-nitrobenzyloxycarbonyl-2-carbamoyl-4-mercaptopyrrolidine was obtained.
-
- a) In the same manner as described in Reference Examples 1-1, 1-2, 1-3, 1-4 and 1-5 but using 300 mg of cis-4-hydroxy-D-proline, 45 mg of (2R,4S)-1-(p-nitrobenzyloxycarbonyl)-2-dimethylcarbamoyl-4-acetyl- thiopyrrolidine was obtained.
- b) In the same manner as described in Reference Example 1-8 but using 30 mg of the thioacetate derivative as obtained in a) above, (2R,4S)-1-(p-nitrobenzyloxycarbonyl)-2-dimethylcarbamoyl-4-mercaptopyrrolidine was obtained.
-
- In the same manner as described in Reference Example 1-2 but using 500 mg of trans-1-p-nitrobenzyloxycarbonyl-4-hydroxy-L-proline and 383 mg or p-nitrobenzyl bromide, trans-1-p-nitrobenzyloxycarbonyl-4-hydroxy-L-proline-p-nitrobenzyl ester was obtained.
- NMR 6 (CDCI3) : 2.20 (3H, m), 3.67 (2H, d, J=3Hz), 4.60 (2H, t, J=8Hz), 5.15 (2H, s), 5.23 (2H, ABq.), 7.47 (4H, d, J = 8.5Hz), 8.15 (4H, d, J = 8.5Hz) ppm
-
-
-
- b) 133 mg of the thus obtained ester derivative was dissolved in 5 ml of a mixture of tetrahydrofuran and water (1:1 by volume), and 0.26 ml of a 1 N aqueous solution of sodium hydroxide was added thereto. After stirring at room temperature for 2.5 hours, 0.3 ml of a 1 N hydrochloric acid aqueous solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with water, dried over sodium sulfate and distilled off to remove the solvent. The residue was subjected to silica gel thin layer chromatography to obtain cis-1-p-nitrobenzyloxycarbonyl-4-ethoxycarbonylthio-L-proline.
- NMR 6 (CDCI3): 1.30 (3H, t, J=7Hz), 4.28 (2H, q, J=7Hz), 5.24 (2H, s), 7.50 (2H, d, J=9Hz), 8.17 (2H, d, J = 9Hz) ppm Reference Example 6-4
- NMR δ (CDCI3) : 1.30 (3H, t, J=8Hz), 2.80 (3H, d, J=5Hz), 4.27 (2H, q, J=8Hz), 5.22 (2H, s), 7.48 (2H, d, J = 9Hz), 8.18 (2H, d, J = 9Hz) ppm b) 82 mg of the methylcarbamoyl derivative as prepared in a) above was dissolved in 4 ml of a mixture of methanol and water (1:1 by volume), and 0.25 ml of a 1 N aqueous solution of sodium hydroxide was added thereto. After stirring at room temperature for 30 minutes, 0.27 ml of a 1 N hydrochloric acid aqueous solution was added thereto. The resulting mixture was extracted with ethyl acetate, and the extract was washed with water, dried over sodium sulfate and distilled off to remove the solvent, thereby to obtain (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-methylcarbamoyl-4-mercaptopyrrolidine.
- NMR δ (CDCI3) : 2.79 (3H, d, J=5Hz), 4.27 (2H, t, J=8Hz), 5.23 (2H, s), 7.50 (2H, d, J=9Hz), 8.20 (2H, d, J=9Hz) ppm
-
-
-
-
- a) In the same manner as described in Reference Example 1-1 but using 10 g of trans-4-hydroxy-L-proline and 23.2 g of S-p-methoxybenzyloxycarbonyl-4,6-dimethyl-2-mercaptopyrimidine,trans-1-(p-methoxybenzyloxycarbonyl)-4-hydroxy-L-proline was obtained.
- NMR δ (CDCI3): 2.23 (2H, m), 3.73 (3H, s), 5.00 (2H, s), 6.78 (2H, d, J=9Hz), 7.20 (2H, d, J=9Hz) ppm b) In the same manner as described in Reference Example 2-1 but using 0.57 g of the proline derivative as prepared in a) above and 0.215 g of benzylamine, trans-1-p-methoxybenzyloxycarbonyl-4-hydroxy-L-benzylprolineamide was obtained.
- NMR δ (CDCI3) : 3.76 (3H, s), 4.35 (4H, m), 4.96 (2H, s), 6.79 (2H, d, J 9Hz), 7.20 (5H, s) ppm c) In the same manner as described in Reference Example 1-3 but using 0.5 g of the benzylprolineamide as prepared in b) above, (2S,4S)-1-p-methoxybenzyloxycarbonyl-2-benzylcarbamoyl-4- acetylthiopyrrolidine was obtained.
- NMR δ (CDCI3) : 2.27 (3H, s), 3.82 (3H, s), 4.42 (2H, d, J=6Hz), 5.05 (2H, s), 6.87 (2H, d, J=8Hz), 7.23 (2H, d, J=8Hz), 7.28 (5H, s) ppm Reference Example 8-2
- NMR δ (CDCI3): 2.28 (3H, s), 3.83 (2H, m), 4.42 (2H, d, J=6Hz), 7.32 (5H, s) ppm
-
- NMR δ (CDCI3): 3.78 (6H, s), 5.00 (1 H, s), 5.80 (1 H, s), 6.84 (4H, d, J = 8.5Hz) ppm
-
- NMR δ (CDCI3): 2.35 (2H, d, J=6Hz), 3.73 (6H, s), 5.80 (1 H, s), 6.78 (4H, d, J=9.OHz), 7.08 (4H, d, J = 9.0Hz) ppm
-
- 1750, 1612, 1510, 1250, 1175, 1033
- NMR δ (CDCI3): 2.36 (2H, d, J=6.5Hz), 3.72 (6H, s), 3.75 (3H, s), 4.83 (2H, s), 5.78 (1 H, s) ppm
-
- NMR δ (CDCI3): 1.23 (3H, d, J=6.5Hz), 2.42 (2H, d, J=7Hz), 3.77 (9H, s), 4.95 (2H, s), 5.78 (1H, s) ppm
-
- NMR δ (CDCI3): 1.35 (3H, d, J = 6.5Hz), 2.40 (2H, d, J = 6.5Hz), 3.09 (1 H, dd, J = 2.5 and 6Hz), 3.73 (6H, s), 3.77 (3H, s), 4.91 (2H, s), 5.18 (2H, s), 5.71 (1 H, s) ppm
-
- NMR δ (CDCI3): 1.35 (3H, d, J=6.5Hz), 2.35 (2H, d, J=6.5Hz), 3.10 (1H, m), 3.73 (6H, s), 5.16 (2H, s), 5.75 (1 H, s), 6.73 (4H, d, J = 9Hz), 7.46 (2H, d, J = 9Hz), 8.10 (2H, d, J = 9Hz) ppm
-
- NMR δ (CDCI3): 1.38 (9H, s), 3.75 (6H, s), 5.17 (4H, s), 5.77 (1 H, br. s), 6.77 (4H, d, J=8.5Hz), 7.45 (4H, d, J = 9Hz), 8.15 (4H, d, J = 9Hz) ppm
-
- NMR δ (CDCI3): 1.41 (3H, d, J=6.5Hz), 2.61 (2H, d, J=6.5Hz), 3.27 (2H, s), 3.76 (6H, s), 5.77 (1 H, s), 6.82 (4H, d, J = 9Hz), 7.47 (2H, d, J = 9Hz), 7.53 (2H, d, J = 9Hz), 8.20 (4H, d, J = 9Hz) ppm
-
- NMR δ (CDCI3): 1.38 (3H, d, J=6.5Hz), 2.95 (2H, d, J=6.5Hz), 3.73 (6H, s), 5.17 (2H, s), 5.24 (2H, s), 5.74 (1H, s), 6.71 (2H, d, J=9Hz), 6.76 (2H, d, J=9Hz), 7.08 (2H, d, J=9Hz), 7.14 (2H, d, J=9Hz), 7.42 (4H, d, J = 9Hz), 8.11 (2H, d, J = 9Hz), 8.16 (2H, d, J = 9Hz) ppm
-
-
- a) 0.55 g of 3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-[3-(p-nitrobenzyloxycarbonyl)-2-oxo-3-diazopropyl]-2-azetidinone was dissolved in 25 ml of degassed dried benzene, and a catalytic amount of rhodium (II) acetate was added thereto. After blowing nitrogen gas into the mixture for about 3 minutes, the mixture was refluxed for 20 minutes, followed by cooling. The catalyst was separated by filtration and washed with benzene. The filtrate and the washing were combined and concentrated under reduced pressure to yield p-nitrobenzyl-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0]heptan-3,7-dione-2-carboxylate.
- b) The keto ester derivative as obtained in a) above was dissolved in 25 ml of dried acetonitrile, and 195 mg of diisopronylethylamine was added thereto under ice-cooling. To the resulting mixture was added dropwise a solution of 300 mg of diphenyl chlorophosphate in 2 ml of dried acetonitrile, followed by stirring for 1 hour. The reaction mixture was diluted with ethyl acetate, washed with water, and dried over magnesium sulfate. The solvent was removed by distillation under reduced pressure to obtain p-nitrobenzyl-5,6-trans-3-(diphenylphosphoryloxy)-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo-[3.2.0]hept-2-ene-7-one-2-carboxylate.
-
-
- To 1.33 g (20 mM) of activated zinc was added 20 ml of dried tetrahydrofuran, and 8.8 ml of a 15% n-hexane solution of diethylaluminium chloride was added thereto in a nitrogen stream under ice-cooling. A solution prepared by dissolving 1.49 g (5.2 mmol) of (3R,4R)-4-acetoxy-3-[(R)-1-(t-butyldimethylsilyloxy)-ethyl]-2-azetidinone (1) and 3.73 g (15.3 mmol) of benzyl a-bromopropionate in 13.3 ml of dried tetrahydrofuran was added dropwise to the mixture over a period of 30 to 40 minutes, followed by stirring for 1 hours. Under ice-cooling, 2.8 ml of pyridine, 13.2 ml of water, 26.5 ml of ethyl acetate and 13.2 ml of a 1 N hydrochloric acid aqueous solution were successively added thereto, and the resulting mixture was filtered using Celite. The filtrate was washed with water, and the organic layer was dried over sodium sulfate and distilled off to remove the solvent. The resulting oily residue was subjected to silica gel column chromatography to obtain an isomeric mixture of 4-(1-benzyloxycarbonyl)-ethyl-3-[(R)-1-(t-butyldimethyl- silyloxy)ethyl]-2-azetidinone.
- The isomeric mixture was separated into each compound by Lober column chromatography using silica gel and 1.5% isopropanol/n-hexane as an eluent to obtain the compound (2a) and the compound (2b) as oily substances.
-
- NMR δ (CDCI3): 0.06 (6H, s), 0.87 (9H, s), 1.16 (3H, d, J=6.5Hz), 1.19 (3H, d, J=7.OHz), 3.71 (1H, dd, J=2 and 10Hz), 5.14 (2H, s), 7.35 (5H, s) ppm
-
- 200 mg of 4-(1-benzyloxycarbonyl)-ethyl-3-[(R)-1-(t-butyl-dimethylsilyloxy)-ethyl]-2-azetidinone (2a) was dissolved in 2 ml or dried dimethylformamide. 126 mg of triethylamine was added to the resulting solution, and then 151 mg of t-butyldimethylsilyl chloride was added thereto, followed by stirring at room temperature overnight. The reaction mixture was diluted with ethyl acetate, washed with water, dried over sodium sulfate and purified by silica gel chromatography to obtain 4-(1-benzyloxycarbonyl)-ethyl-3-[(R)-1-(t-butyl- dimethylsilyloxy)-ethyl]-1-(t-butyldimethylsilyl)-2-azetidinone (3a).
-
-
-
- To a solution of 261 mg of (5R,6S,8R)-p-nitrobenzyl-3-ethylthio-6-(1-hydroxyethyl)-1-aza bicyclo[3.2.0]-hept-2-ene-7-one-4-thia-2-carboxylate in 28 ml of dried methylene chloride, 144 mg of m-chloroperbenzoic acid was added at -45 ° C in a nitrogen stream, followed by stirring at -20 to -40 °C for 2 hours. The reaction mixture was washed with a saturated aqueos solution of sodium bicarbonate and then with water, dried over sodium sulfate and distilled off to remove the solvent. The resulting residue was purified by silica gel chromatography to obtain (5R,6S,8R)-p-nitrobenzyl-3-ethylsulfinyl-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]-hept-2-ene-7-one-4-thia-2-carboxylate.
- NMR δ (CDCI3): 5.74 (3/5H, d, J = 1.5Hz), 5.87 (2/5H, d, J = 1.5Hz) ppm
-
- a) 122 mg of (5R,6S,8R)-p-nitrobenzyl-3-(diphenylphosphoryloxy-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0] hept-2-ene-7-one-2-carboxylate was dissolved in 3 ml of dry acetonitrile, and 31 mg of diisopropylethylamine was added thereto in a nitrogen stream under ice-cooling. Then, 60 mg of [2S,4S]-1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl-4-mercaptopyrrolidine was added to the mixture, followed by stirring for 1 hour. The reaction solution was diluted with ethyl acetate, washed with water, dried over magnesium sulfate and the solvent was distilled off. The residue was purified by silica gel thin layer chromatography to obtain 95 mg of (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl)-pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0] hept-2-ene-7-one-2-carboxylate.
- b) 95 mg of (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[4-(1-_p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl)-pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylate was dissolved in 20 ml of dioxane, and a morpholinopropanesulfonic acid buffer solution (pH = 7.0, 10 ml) and platinum oxide (35 mg) were added thereto. The mixture was then hydrogenated under a hydrogen pressure of 3.5 atm. for 6.5 hours. The catalyst was filtered off and dioxane was distilled off under reduced pressure. The residual solution was washed with ethyl acetate, and the aqueous layer was again distilled under reduced pressure to remove the organic solvent. The residual solution was subjected to polymer chromatography (CHP-20P) to obtain (5R,6S, 8R,2'S,4'S)-3-[4-(2-dimethylaminecarbonyl)pyrrolidinylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylic acid from the fraction eluted with water.
-
- a) In the same manner as described in Example 1-1 (a) but using 129 mg of (5R,6S,8R)-p-nitrobenzyl-3-(diphenylphosphoryloxy)-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylate and 67 mg of [2S,4R]-1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl-4-mercaptopyrrolidine, there was obtained 40 mg of (5R,6S,8R,2'S,4'R)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl)-pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-carboxylate.
- b) In the same manner as described in Example 1-1(b) but using 40 mg of (5R,6S,8R,2'S,4'R)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl)-pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylate, there was obtained (5R,6S,8R,2'S,4' R)-3-[4-(2-dimethylaminocarbonyl)-pyrrolidinylthio]-6-(1-hydroxyethyl)-1-azabicyclo-[3.2.0]hept-2-ene-7-one-2-carboxylic acid.
-
- a) In the same manner as described in Example 1-1 (a) but using 61 mg of (5R,6S,8R)-p-nitrobenzyl-3-(diphenylphosphoryloxy)-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylate and 31 mg of [2R,4S]-1-p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl-4-mercaptopyrrolidine, there was obtained 37 mg of (5R,6S,8R,2'R,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl)-pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylate.
- b) In the same manner as described in Example 1-1(b) but using 37 mg of (5R,6S,8R,2'R,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl)-pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylate, there was obtained (5R,6S,8R,2' R,4'S)-3-[4-(2-dimethylaminocarbonyl)-pyrrolidinylthio]-6-(1-hydroxyethyl)-1-azabicyclo-[3.2.0]hept-2-ene-7-one-2-carboxylic acid.
-
- NMR δ (CDCI3): 1.49 (3H, d, J=6.5Hz), 2.98 (3H, s), 3.09 (3H, s), 5.25 (4H, s), 5.26 and 5.44 (2H, ABq, J = 14Hz), 8.20 (6H, d, J = 8.5Hz) [α]30 D + 23.3 ° (c = 0.329, acetone)
- b) In the same manner as described in Example 1-1(b) but using 35 mg of (5R,6S,8R,2'R,4'R)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl)-pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylate, there was obtained (5R,6S,8R,2'R,4'R)-3-[4-(2-dimethylaminocarbonyl)-pyrrolidinylthio]-6-(1-hydroxyethyl)-1-azabicyclo-[3.2.0]hept-2-ene-7-one-2-carboxylic acid.
-
- NMR δ (CDCI3): 1.30 (3H, d, J =7.OHz), 1.35 (3H, d, J = 6.5Hz), 2.99 (3H, s), 3.02 (3H, d, J = 15Hz), 5.21 (2H, s), 5.20 and 5.43 (2H, ABq, J = 14Hz), 7.51 (2H, d, J = 8.5Hz), 7.64 (2H, d, J = 8.5Hz), 8.20 (4H, d, J = 8.5Hz] b) 25 mg of (4R,5S,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl)-pyrrolidinylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylate was dissolved in a mixture of 1.9 ml of tetrahydrofuran and 0.3 ml of ethanol, and the mixture was hydrogenated in a morpholinopropanesulfonic acid buffer solution (pH = 7.0, 1.9 ml) under atmospheric pressure of hydrogen for 3 hours at room temperature in the presence of 30 mg of 10% palladium-carbon, which had been activated in hydrogen atmosphere for 1 hour followed by washing with water. After filtering off the catalyst, tetrahydrofuran and ethanol were distilled off under reduced pressure, and the residual solution was washed with ethyl acetate. The aqueous layer was again distilled under reduced pressure to remove organic solvents, and the residual solution was subjected to polymer chromatography (CHP-20P) to obtain (4R,5S,6S,8R,2'S,4'S)-3-[4-(2-dimethylaminocarbonyl)-pyrrolidinylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-l-one-2-carboxylic acid from the fraction eluted with water.
- NMR δ (D2O): 1.21 (3H, d, J=7.OHz), 1.29 (3H, d, J=6.5Hz), 1.92 (1H, m), 2.99 (3H, s), 3.06 (3H, s)
-
- a) 61 mg of (4R,5R,6S,8R)-p-nitrobenzyl-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0] hept-3,7-dione-2-carboxylate was dissolved in 6 ml of dry acetonitrile, and 72 mg of diisopropylethylamine and then 55 mg of diphenyl chlorophosphate were added thereto in a nitrogen stream under ice-cooling, followed by stirring for 2.5 hours. 77 mg of [2S,4S]-1-p-nitrobenzyloxycarbonyl-2-(1-pyrrolidinocarbonyl)-4-mercaptopyrrolidine was added to the mixture, followed by stirring for 1 hour. The reaction solution was diluted with ethyl acetate, washed with water, dried over magnesium sulfate, and the solvent was distilled off. The residue was purified by silica gel thin layer chromatography to obtain 51 mg of (4R,5S, 6S,6R,2'S,4'S)-p-nitrobenzyl-3-[(1-p-nitrobenzyloxycarbonyl-2-(1-pyrrolidinocarbonyl)-pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0] hept-2-ene-7-one-2-carboxylate.
- NMR δ (CDCI3) : 1.30 (3H, d, J=7.OHz), 1.34 (3H, d, J=6.5Hz), 5.21 (2H, s), 5.20 and 5.44 (2H, ABq, J = 14Hz), 7.50 (2H, d, J = 8.5Hz), 7.64 (2H, d, J = 8.5Hz), 8.20 (4H, d, J = 8.5Hz) b) 50 mg of (4R,5S,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[1-p-nitrobenzyloxycarbonyl-2-(1-pyrrolidinocarbonyl)-pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylate was dissolved in a mixture of 3.9 ml of tetrahydrofuran and 0.6 ml of ethanol, and the mixture was hydrogenated in a morpholinopropanesulfonic acid buffer solution (pH = 7.0, 3.9 ml) under atmospheric pressure of hydrogen for 4.5 hours at room temperature in the presence of 60 mg of 10% palladium-carbon, which had been activated in hydrogen atmosphere for 1 hour followed by washing with water. After filtering off the catalyst, tetrahydrofuran and ethanol were distilled off under reduced pressure, and the residual solution was washed with ethyl acetate. The aqueous layer was again distilled under reduced pressure to remove organic solvents, and the residual solution was subjected to polymer chromatography (CHP-20P) to obtain (4R,5S,6S,8R,2'S,4'S)-3-[2-(1-pyrrolidinocarbonyl)-pyrrolidin-4-ylthio] 4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0] hept-2-ene-7-one-2-carboxylic acid from the fraction eluted with a 2% aqueous tetrahydrofuran solution.
- NMR 6 (D20); 1.20 (3H, d, J=7.OHz), 1.29 (3H, d, J=6.5Hz), 1.95 (6H, m), 3.46 (6H, m), 3.72 (1H, dd, J = 6.5 and 12Hz), 4.02 (1 H, quintet, J = 6.5Hz)
-
- a) 172 mg of (5R,6S,8R)-p-nitrobenzyl-3-(diphenylphosphoryloxy)-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0] hept-2-ene-7-one-2-carboxylate was dissolved in 2.3 ml of dry acetonitrile, and to the solution were added a solution of 59 mg of diisopropylethylamine in 0.7 ml of dry acetonitrile and then a solution of 94 mg of [2S,4S]-1-p-nitrobenzyloxycarbonyl-2-(3-pyrroline-1-carbonyl)-4-mercaptopyrrolidine in 1 ml of dry acetonitrile, in a nitrogen stream and under ice-cooling, followed by stirring for 15 minutes. The reaction solution was diluted with diethyl ether, washed with water, and the insoluble material in the ether layer was dissolved with addition of methylene chloride. The methylene chloride and ether layer was dried over magnesium sulfate and the solvent was distilled off. The residue was purified by silica gel thin layer chromatography to obtain 182 mg of (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-{4-[l-p-nitrobenzyloxycarbonyl-2-(3-pyrroline-1-carbonyl)]-pyrrolidinylthio}-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylate.
- NMR δ (CDCI3): 1.49 (3H, d, J = 6.2Hz), 5.26 (4H, s), 8.18 (6H, d, J=8.8Hz) b) 182 mg of (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-{4-[1-p-nitrobenzyloxycarbonyl-2-(3-pyrroline-1-carbonyl)]-pyrrolidinylthio}-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylate was dissolved in a mixture of 12.6 ml of tetrahydrofuran and 2 ml of ethanol, and the solution was hydrogenated in a morpholinopropanesulfonic acid buffer solution (pH = 7.0, 12.6 ml) at room temperature under atmospheric pressure of hydrogen for 7 hours in the presence of 219 mg of 10% palladium-carbon, which had been activated in hydrogen atmosphere for 1 hour, followed by washing with water. After filtering off the catalyst, tetrahydrofuran and ethanol were distilled off under reduced pressure, and the residual solution was washed with ethyl acetate. The aqueous layer was again distilled under reduced pressure to remove organic solvents, and the residual solution was subjected to polymer chromatography (CHP-20P) to obtain (5R,6S,8R,2'S,4'S)-3-{4-[2-(3-pyrroline-1-carbonyl)-pyrrolidinylthio}-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylic acid from the fraction eluted with a 2% aqueous tetrahydrofuran solution.
- NMR δ (D2O): 1.26 (3H, d, J=6.4Hz), 3.18 (1H, dd, J=2.1 and 9.0Hz), 3.77 (1H, dd, J=7.0 and 12.0Hz), 5.89 (2H, br. s)
-
- a) Following the procedures as described in Example 1-1 (a) using 68 mg of (5R,6S,8R)-p-nitrobenzyl-3-(diphenylphosphoryloxy)-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylate and 33 mg of [2S,4S]-1-p-nitrobenzyloxycarbonyl-2-carbamoylmethylaminocarbonyl-4-mercaptopyrrolidine, there was obtained 61 mg of crystalline (5R,6S,8R,2'S, 4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-carbamoylmethylaminocarbonyl)-pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylate by filtration.
- NMR δ (CDCI3): 1.50 (3H, d, J=6.5Hz), 5.23 (4H, s), 7.50 (4H, d, J=8.5Hz), 8.21 (6H, d, J = 8.5Hz) m.p.: 184-189 ° C (dec.) b) 30 mg of (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-carbamoyl- methylaminocarbonyl)-pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3.2.0]hept-2- ene-7-one-2-carboxylate was dissolved in a mixture of 3.1 ml of tetrahydrofuran and 1 ml of dimethylformamide, and the solution was hydrogenated in the presence of a morpholinopropanesulfonic acid buffer solution (pH = 7.0, 3.1 ml) at room temperature under atmospheric pressure of hydrogen for 5 hours in the presence of 37 mg of 10% palladium-carbon which had been activated in hydrogen atmosphere for 1 hour followed by washing with water. After filtering off the catalyst, tetrahydrofuran was distilled off under reduced pressure, and the residual solution was washed with methylene chloride. The aqueous layer was distilled to remove the organic solvents, and the residual solution was subjected to polymer chromatography (CHP-20P) to obtain (5R,6S,8R,2'S,4'S)-3-[4-(2-carbamoylmethylaminocarbonyl)-pyrrolidinylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-l-one-2-carboxylic acid from the fraction eluted with water.
- NMR δ (D2O): 1.26 (3H, d, J = 6.6Hz), 1.86 (1 H, m), 3.20 (2H, dd, J=7.5 and 14.7Hz), 3.38 (1 H, dd, J = 3.0 and 6.7Hz), 4.02 (1 H, t, J=9.OHz)
-
- a) To a solution of 45 mg of (5R,6S,8R)-p-nitrobenzyl-3-ethylsulfinyl-6-(1-hydroxyethyl)-1-azabicyclo-[3.2.0]hept-2-ene-7-one-4-thia-2-carboxylate in 0.8 ml of dry acetonitrile were added a solution of 30 mg of diisopropylethylamine in 0.3 ml of dry acetonitrile and then a solution of 81 mg of (2'S,4'S)-1'-p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl-4'-mercaptopyrrolidine in 0.6 ml of dry acetonitrile under nitrogen stream at -40 ° C, followed by stirring the mixture at -40 ° C to -45 ° C for 10 minutes. The reaction solution was diluted with ethyl acetate, washed with a saturated aqueous solution of sodium chloride, dried over sodium sulfate, and the solvent was distilled off. The resulting residue was purified by silica gel chromatography to obtain (5R,6S, 8R,2'S,4'S)-p-nitrobenzyl-3-[(1-p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl)-pyrrolidin-4-ylthio]-6-(1-hydroxy ethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-4-thia-2-carboxylate. [α]29 D +52° (C=0.43, CHCI3)
- b) 204 mg of 5% palladium-carbon was suspended in a mixture of ethanol (3.8 ml) and water (3.8 ml) and hydrogenated at room temperature under atmospheric pressure for 1 hour. The catalyst was filtered, washed with water, suspended in a phosphate buffer (pH = 6.86, 5.1 ml), and added to a solution of 68 mg of (5R,6S,8R, 2'S,4'S)-p-nitrobenzyl-3-[(1-p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl)-pyr- rolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-4-thia-2-carboxylate in 7.7 ml of tetrahydrofuran. The mixture was hydrogenated at room temperature and under atmospheric pressure for 3 hours. After filtering off the catalyst, tetrahydrofuran was distilled off under reduced pressure. The residual solution was washed with ethyl acetate, and the aqueous layer was again distilled under reduced pressure to remove the organic solvents. The resulting residual solution was purified by CHP-20P column chromatography to obtain (5R,6S,8R,2'S,4'S)-2-[(2-dimethylaminocarbonyl)-pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3.2.0]hept-2-ene-7-one-4-thia-2-carboxylic acid.
- The compounds shown in Table 6 below were prepared from the corresponding mercaptan derivatives. In Table 6, "HE" represents (R)-1-hydroxyethyl group, and "PNZE" represents (R)-1-p-nitrobenzyloxycar- bonyloxyethyl group.
-
-
Claims (56)
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58081443A JPS59205379A (en) | 1983-05-09 | 1983-05-09 | Novel beta-lactam compound and production thereof |
JP81443/83 | 1983-05-09 | ||
JP108472/83 | 1983-06-15 | ||
JP58108472A JPS601186A (en) | 1983-06-15 | 1983-06-15 | Novel beta-lactam compound and its preparation |
JP58127485A JPS6019787A (en) | 1983-07-12 | 1983-07-12 | Novel beta-lactam compound and its preparation |
JP58166938A JPS6058987A (en) | 1983-09-09 | 1983-09-09 | Novel beta-lactam compound and production thereof |
JP166938/83 | 1983-09-09 | ||
JP127485/83 | 1983-09-26 | ||
JP212857/83 | 1983-11-11 | ||
JP58212857A JPS60104088A (en) | 1983-11-11 | 1983-11-11 | Novel beta-lactam compound and its preparation |
JP23497/84 | 1984-02-10 | ||
JP59023497A JPS60166683A (en) | 1984-02-10 | 1984-02-10 | Novel beta-lactam compound and its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0126587A1 EP0126587A1 (en) | 1984-11-28 |
EP0126587B1 true EP0126587B1 (en) | 1995-04-19 |
Family
ID=27549102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP84303128A Expired - Lifetime EP0126587B1 (en) | 1983-05-09 | 1984-05-09 | Carboxylic thio-pyrrolidinyl beta-lactam compounds and production thereof |
Country Status (9)
Country | Link |
---|---|
US (3) | US4943569A (en) |
EP (1) | EP0126587B1 (en) |
AT (1) | ATE121402T1 (en) |
CA (1) | CA1283906C (en) |
DE (1) | DE3486382T2 (en) |
ES (1) | ES8600305A1 (en) |
HK (1) | HK183095A (en) |
MX (1) | MX9203063A (en) |
NL (1) | NL950019I2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2266590A2 (en) | 2002-02-22 | 2010-12-29 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
CN101711251B (en) * | 2007-06-26 | 2011-12-28 | 山东轩竹医药科技有限公司 | 1beta-methylcarbapenem antibiotics,the pharmaceutical composition and use thereof |
WO2017158616A1 (en) | 2016-03-16 | 2017-09-21 | Orchid Pharma Ltd. | Carbapenem compounds |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1283906C (en) * | 1983-05-09 | 1991-05-07 | Makoto Sunagawa | .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF |
JPS60202886A (en) * | 1984-03-27 | 1985-10-14 | Sankyo Co Ltd | 1-substituted carbapenem-3-carboxylic acid derivative and its preparation |
DE3579888D1 (en) * | 1984-11-08 | 1990-10-31 | Sumitomo Pharma | CARBAPENE COMPOUNDS AND THEIR PRODUCTION. |
JPS61275279A (en) * | 1984-12-25 | 1986-12-05 | Sankyo Co Ltd | Carbapenem compound |
US4806637A (en) * | 1986-03-17 | 1989-02-21 | Schering Corporation | 6-(Hydroxyethyl)-2-(heterocyclylthio)-penem-3-carboxylates |
ES2051700T3 (en) * | 1986-03-27 | 1994-07-01 | Sumitomo Pharma | A PROCESS FOR THE PREPARATION OF A BETA-LACTAMA COMPOUND. |
IE60588B1 (en) * | 1986-07-30 | 1994-07-27 | Sumitomo Pharma | Carbapenem compound in crystalline form, and its production and use |
KR880006244A (en) * | 1986-11-24 | 1988-07-22 | 후지사와 도모 기찌 로 | 3-Pyrrolidinylthio-1-azabibischloro [3.2.0] hapt2-ene-2-carboxylic acid compound and preparation method thereof |
EP0272455B1 (en) * | 1986-11-24 | 1993-02-10 | Fujisawa Pharmaceutical Co., Ltd. | 3-Pyrrolidinylthio-1-azabicyclo [3.2.0] hept-2-ene-2-carboxylic acid compounds |
US4925838A (en) * | 1988-03-18 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds |
FI91258C (en) * | 1988-04-01 | 1994-06-10 | Sankyo Co | Process for the preparation of 2- (heterocyclylthio) carbapenem derivatives useful as medicaments |
US5242914A (en) * | 1988-04-01 | 1993-09-07 | Sankyo Company, Limited | 2-(heterocyclylthio) carbapenem derivatives, their preparation and their use as antibiotics |
GB8811237D0 (en) * | 1988-05-12 | 1988-06-15 | Fujisawa Pharmaceutical Co | 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives |
US4963544A (en) * | 1988-05-23 | 1990-10-16 | Fujisawa Pharmaceutical Company, Ltd. | 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds |
US4876365A (en) * | 1988-12-05 | 1989-10-24 | Schering Corporation | Intermediate compounds for preparing penems and carbapenems |
EP0406863B1 (en) * | 1989-07-06 | 1995-05-24 | Banyu Pharmaceutical Co., Ltd. | Cyclic amidinylthiocarbapenem derivatives |
GB8923844D0 (en) * | 1989-10-23 | 1989-12-13 | Fujisawa Pharmaceutical Co | Carbapenem compounds |
EP0435320B1 (en) * | 1989-12-29 | 1994-10-05 | Banyu Pharmaceutical Co., Ltd. | 2(2-Cyclopropylpyrrolidin-4-ylthio)-carbapenem derivatives |
CA2036163C (en) * | 1990-02-14 | 2001-06-19 | Makoto Sunagawa | Novel beta-lactam compounds and their production |
US5227376A (en) * | 1990-02-14 | 1993-07-13 | Sumitomo Pharmaceuticals Co., Ltd. | β-lactam compounds and their production |
NZ237191A (en) * | 1990-02-23 | 1992-12-23 | Sankyo Co | 2-((substituted amide) substituted heterocyclylthio) carbpen-2-em derivatives and pharmaceutical compositions |
GB9107363D0 (en) * | 1991-04-08 | 1991-05-22 | Ici Plc | Antibiotic compounds |
US5554606A (en) * | 1990-03-12 | 1996-09-10 | Zeneca Limited | Antibiotic compounds |
TW198034B (en) * | 1990-03-27 | 1993-01-11 | Manyu Seiyaku Kk | |
US5189158A (en) * | 1991-03-20 | 1993-02-23 | American Cyanamid Company | 4-substituted azetidinones as precursors to 2-substituted-3-carboxy carbapenem antibiotics and a method of producing them |
GB9107341D0 (en) * | 1991-04-08 | 1991-05-22 | Ici Plc | Antibiotic compounds |
RU2093514C1 (en) * | 1991-06-04 | 1997-10-20 | Санкио Компани Лимитед | 1-methylcarbapenem derivatives and method of preparation thereof |
US5712267A (en) * | 1991-06-04 | 1998-01-27 | Sankyo Company,. Limited | Carbapenem derivatives, their preparation and their use as antibiotics |
JP3048196B2 (en) * | 1991-06-20 | 2000-06-05 | 第一製薬株式会社 | Carbapenem derivatives |
JP3091297B2 (en) * | 1992-01-10 | 2000-09-25 | 住友製薬株式会社 | Pyrrolidine derivative and method for producing the same |
GB9202298D0 (en) | 1992-02-04 | 1992-03-18 | Ici Plc | Antibiotic compounds |
HU218676B (en) * | 1992-03-11 | 2000-10-28 | Sankyo Co. Ltd. | Antimicrobial carbapenem derivatives pharmaceutical compositions comprising such compounds and process for producing them |
CA2091309A1 (en) * | 1992-03-26 | 1993-09-27 | Frederic H. Jung | Antibiotic compounds |
GB9304156D0 (en) * | 1992-03-26 | 1993-04-21 | Zeneca Ltd | Antibiotic compounds |
JP3233434B2 (en) * | 1992-04-01 | 2001-11-26 | 塩野義製薬株式会社 | Carbapenem derivatives |
EP0581502B1 (en) * | 1992-07-21 | 1998-10-21 | Zeneca Limited | Antibiotic carbapenem compounds |
CA2099818A1 (en) * | 1992-07-21 | 1994-01-22 | Frederic H. Jung | Antibiotic compounds |
EP0581501B1 (en) * | 1992-07-21 | 1998-09-09 | Zeneca Limited | Antibiotic carbapenem compounds |
CA2099811A1 (en) * | 1992-07-21 | 1994-01-22 | Frederic H. Jung | Antibiotic compounds |
CA2099817A1 (en) * | 1992-07-21 | 1994-01-22 | Frederic H. Jung | Antibiotic compounds |
EP0590885B1 (en) * | 1992-09-28 | 2000-03-15 | Zeneca Limited | Antibiotic carbapenem compounds |
CA2106141A1 (en) * | 1992-09-28 | 1994-03-29 | Michael J. Betts | Antibiotic compounds |
CA2106330A1 (en) * | 1992-10-07 | 1994-04-08 | Patrice J. Siret | Antibiotic compounds |
US5602118A (en) * | 1993-03-16 | 1997-02-11 | American Cyanamid Company | 2-thiosubstituted carbapenems |
AU4912393A (en) * | 1993-06-15 | 1994-12-22 | Dong Kook Pharmaceutical Co., Ltd. | 1-beta-methyl-2-thiolic carbapenem derivatives |
CA2155448A1 (en) * | 1994-08-11 | 1996-02-12 | Katerina Leftheris | Inhibitors of farnesyl protein transferase |
GB9515975D0 (en) | 1995-08-04 | 1995-10-04 | Zeneca Ltd | Chemical compounds |
CA2241092C (en) * | 1995-12-21 | 2004-04-27 | Sankyo Company, Limited | 1-methylcarbapenem derivatives |
CN1093861C (en) * | 1996-04-26 | 2002-11-06 | 三共株式会社 | 1-methylcarbapenem derivatives |
EP0923545A1 (en) | 1996-08-17 | 1999-06-23 | Zeneca Limited | 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors |
EP0937079A4 (en) * | 1996-10-28 | 2001-01-24 | Merck & Co Inc | Stabilized carbapenem antibiotic compositions and method of making |
US6297231B1 (en) | 1996-10-28 | 2001-10-02 | Merck & Co., Inc. | Stabilized carbapenem antibiotic compositions and method of making |
HUP0000952A3 (en) | 1997-02-07 | 2000-12-28 | Kyoto Pharma Ind | Carbapenem compounds, process for their preparation and pharmaceutical compositions containing them |
US6143885A (en) * | 1997-08-27 | 2000-11-07 | Merck & Co., Inc. | Preparation of beta-methyl carbapenem intermediates |
DE69811382T2 (en) * | 1997-09-13 | 2003-10-23 | Korea Inst Sci & Tech | CARBAPEN DERIVATIVES AND PRODUCTION METHOD THEREFOR |
ATE337321T1 (en) | 1998-05-01 | 2006-09-15 | Kyoto Pharma Ind | CABAPENEM DERIVATIVES, THEIR USE AND THEIR INTERMEDIATE PRODUCTS |
US6271222B1 (en) * | 1998-05-28 | 2001-08-07 | Merck & Co., Inc. | Penem antibacterial compounds, compositions and methods of treatment |
US6734205B2 (en) | 1999-12-16 | 2004-05-11 | Sumitomo Pharmaceuticals Company Limited | Substituted guanidine derivatives |
GB9930317D0 (en) | 1999-12-22 | 2000-02-09 | Zeneca Ltd | Novel compounds |
GB9930318D0 (en) | 1999-12-22 | 2000-02-09 | Zeneca Ltd | Novel compounds |
KR100345465B1 (en) * | 2000-07-05 | 2002-07-26 | 한국과학기술연구원 | Novel 1β-Methylcarbapenem derivatives and process of preparation thereof |
US6444829B1 (en) * | 2000-07-19 | 2002-09-03 | Hoffmann-La Roche Inc. | Pyrrolidine compounds |
CN1620433A (en) * | 2000-07-19 | 2005-05-25 | 霍夫曼-拉罗奇有限公司 | Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme |
BR0209970A (en) * | 2001-05-21 | 2004-04-06 | Kyoto Pharma Ind | Carbapenem Compound |
UA78524C2 (en) * | 2001-09-26 | 2007-04-10 | Merck & Co Inc | A process for preparation of carbapenem compounds |
AU2002331885B2 (en) | 2001-09-26 | 2007-07-26 | Merck & Co., Inc. | Crystalline forms of ertapenem sodium |
KR101159575B1 (en) | 2004-01-30 | 2012-07-06 | 얀센 알 앤드 디 아일랜드 | Hcv ns-3 serine protease inhibitors |
SE0400199D0 (en) * | 2004-01-30 | 2004-01-30 | Medivir Ab | HCV Protease Inhibitors |
ES2370829T3 (en) * | 2004-06-02 | 2011-12-23 | Sandoz Ag | INTERMEDIATE PRODUCT OF MEROPENEM IN CRYSTAL FORM. |
EP2495245A3 (en) * | 2004-06-10 | 2012-12-19 | FOB Synthesis, Inc. | Gram-positive carbapenem antibacterials and processes for their preparation |
WO2006035300A2 (en) * | 2004-09-30 | 2006-04-06 | Ranbaxy Laboratories Limited | A process for the preparation of meropenem |
WO2007004028A2 (en) * | 2005-06-30 | 2007-01-11 | Ranbaxy Laboratories Limited | Processes for the preparation of penems and its intermediate |
US20070197781A1 (en) * | 2005-07-29 | 2007-08-23 | Neera Tewari | Processes for the preparation of carbapenems |
PE20070211A1 (en) | 2005-07-29 | 2007-05-12 | Medivir Ab | MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS |
EP1926732B1 (en) | 2005-09-05 | 2013-11-06 | Ranbaxy Laboratories Limited | A process for the preparation of carbapenem compounds |
US8148520B2 (en) * | 2005-09-15 | 2012-04-03 | Orchid Chemicals And Pharmaceuticals Limited | Process for the preparation of beta-lactam antibiotic meropenem trihydrate |
CN100347175C (en) * | 2006-03-14 | 2007-11-07 | 深圳市海滨制药有限公司 | Preparation method of beta-methyl carbon penicillenic intermediate |
CN100422184C (en) * | 2006-03-14 | 2008-10-01 | 深圳市海滨制药有限公司 | Preparation method of meluopeinan |
WO2007104221A1 (en) * | 2006-03-14 | 2007-09-20 | Shenzhen Haibin Pharmaceutical Co., Ltd. | A process for the preparation of meropenem |
TW200801004A (en) | 2006-03-28 | 2008-01-01 | Kaneka Corp | Improved process for producing carbapenem compound |
CN101041632A (en) * | 2007-04-28 | 2007-09-26 | 浙江耐司康药业有限公司 | Preparation method of penem drug branched chain intermediate-mercaptan derivative |
CN101323615B (en) * | 2007-06-11 | 2010-10-13 | 山东轩竹医药科技有限公司 | Pennem derivates containing formamide heterocycle sulfonic acid amide sulfhydryl pyrrolidine |
CN101333219B (en) * | 2007-06-26 | 2010-10-13 | 山东轩竹医药科技有限公司 | Penem derivates with mercapto pyrrolidine formamide benzene alkyl heterocycle |
CN101367809B (en) * | 2007-06-28 | 2011-04-27 | 山东轩竹医药科技有限公司 | Penem derivant containing sulfhydryl pyrrolidine formhydrazide |
WO2009000210A1 (en) | 2007-06-28 | 2008-12-31 | Zhenhua Huang | Novel carbapenem derivatives |
JP2010540433A (en) * | 2007-09-20 | 2010-12-24 | クジェ ファーマシューティカル インダストリアル カンパニー リミテッド | Synthetic intermediate acid addition salts of carbapenem antibiotics and process for producing the same |
US20090082327A1 (en) * | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched meropenem |
US20090216010A1 (en) * | 2008-02-22 | 2009-08-27 | Wei-Hong Tseng | Crystalline carbapenem compound and produced method thereof |
EP2098525A1 (en) | 2008-02-26 | 2009-09-09 | Savior Lifetec Corporation | Crystalline carbapenem compound and produced method thereof |
US8097719B2 (en) * | 2008-07-15 | 2012-01-17 | Genesen Labs | Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem |
US8841444B2 (en) * | 2008-07-30 | 2014-09-23 | Ranbaxy Laboratories Limited | Process for the preparation of carbapenem compounds |
CN101817837A (en) * | 2009-02-13 | 2010-09-01 | 山东轩竹医药科技有限公司 | Carbapenem derivative containing azabicyclo |
US9233963B2 (en) | 2009-03-13 | 2016-01-12 | Daewoong Pharmaceutical Co., Ltd. | Method for preparing meropenem using zinc powder |
US9120808B2 (en) | 2009-09-15 | 2015-09-01 | Nabriva Therapeutics Ag | Substituted clavulanic acid |
WO2011048583A1 (en) | 2009-10-23 | 2011-04-28 | Ranbaxy Laboratories Limited | Process for the preparation of carbapenem compounds |
US8318716B2 (en) | 2009-12-31 | 2012-11-27 | Kbp Biosciences Co., Ltd. | Carbapenem derivatives |
KR101862041B1 (en) | 2010-06-18 | 2018-05-29 | 포브 신세시스 | Carbapenem antibacterials with gram-negative activity |
CN107020094B (en) * | 2011-10-31 | 2019-10-11 | 陶氏技术投资有限责任公司 | Produce the method for epoxidation catalyst and the epoxidizing method using the epoxidation catalyst |
WO2014070774A1 (en) * | 2012-10-29 | 2014-05-08 | Southern Methodist University | Methods of generating beta-lactamase resistant carbapenem compounds |
KR101331762B1 (en) | 2012-12-28 | 2013-11-20 | 주식회사 대웅제약 | Process for preparing meropenem.trihydrate |
KR102144777B1 (en) | 2013-06-19 | 2020-08-18 | 제이더블유중외제약 주식회사 | A process for the preparation of crystalline Meropenem trihydrate |
CN103894210B (en) * | 2014-04-29 | 2015-08-12 | 西安凯立化工有限公司 | A kind of Meropenem synthesis palladium carbon catalyst applied mechanically |
EP3269718A1 (en) | 2016-07-12 | 2018-01-17 | Evonik Degussa GmbH | Process for the deprotection of a carbapenem by heterogeneous catalytic hydrogenation with hydrogen in the presence of an organic amine |
EP3523309B1 (en) * | 2016-10-10 | 2024-04-17 | The Johns Hopkins University | Antibacterial agents against d,d- and l,d-transpeptidases |
CA3066661A1 (en) | 2017-06-09 | 2018-12-13 | Fob Synthesis, Inc. | Carbapenem compounds and compositions for the treatment of bacterial infections |
CN111960984B (en) * | 2020-09-11 | 2023-04-28 | 江西如益科技发展有限公司 | Preparation method of synthetic doripenem side chain intermediate |
CN114163371A (en) * | 2021-12-21 | 2022-03-11 | 天津市敬业精细化工有限公司 | Meropenem side chain optical isomer, preparation method and application thereof, and detection method of impurities in Meropenem side chain |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4168314A (en) * | 1977-11-17 | 1979-09-18 | Merck & Co., Inc. | 6-(1'-Hydroxyethyl)-2-aminoethylthio-pen-2-em-3-carboxylic acid |
EP0042026B1 (en) * | 1978-02-02 | 1986-01-08 | Ciba-Geigy Ag | 3,4-disubstituted azetidin-2-on compounds and process for their preparation |
DK446179A (en) * | 1978-10-24 | 1980-05-29 | Merck & Co Inc | PROCEDURE FOR PREPARING SUBSTITUTED 1-CARBADETHYAPE-2-EM-3-CARBOXYL ACIDS |
EP0011173B1 (en) * | 1978-11-01 | 1983-05-11 | Sanraku-Ocean Co., Ltd. | Process for producing antibiotic beta-lactam compounds |
JPS5625110A (en) * | 1978-12-18 | 1981-03-10 | Bristol Myers Co | Antibacterial |
EP0017992A1 (en) * | 1979-04-19 | 1980-10-29 | Merck & Co. Inc. | 2-Substituted-6-substituted-1-carbadethiapen-2-em-3-carboxylic acids, processes for preparing them, antibiotic pharmaceutical compositions containing same and process for preparing intermediates |
US4383946A (en) * | 1980-03-27 | 1983-05-17 | Merck & Co., Inc. | Process for the preparation of 1-carbapenems and intermediates via silyl-substituted dithioacetals |
GB2089340B (en) * | 1980-10-25 | 1984-09-19 | Beecham Group Ltd | -lactam antibiotics their preparation and their use |
JPS5778883A (en) * | 1980-11-05 | 1982-05-17 | Toshiaki Betsumiya | Solid puzzle |
EP0057565A1 (en) * | 1981-02-04 | 1982-08-11 | Beecham Group Plc | Beta-lactam antibiotics, their preparation and use |
EP0061231A1 (en) * | 1981-02-04 | 1982-09-29 | Beecham Group Plc | Process for the preparation of azabicyclo(3.2.0)-hept-2-ene derivatives |
JPS57176988A (en) * | 1981-04-09 | 1982-10-30 | Sankyo Co Ltd | Penam-3-carboxylic acid derivative and its preparation |
ES514240A0 (en) * | 1981-08-03 | 1984-04-16 | Merck & Co Inc | A PROCEDURE FOR THE PREPARATION OF NEW 2-CARBAMIMIDOIL-1-, CARBADESTIAPEN-2-EN-3-CARBOXYLATED ACID DERIVATIVES. |
US4552873A (en) * | 1981-08-19 | 1985-11-12 | Sankyo Company Limited | Carbapenem compounds, and compositions containing them |
EP0089139A2 (en) * | 1982-03-16 | 1983-09-21 | Beecham Group Plc | Antibiotics, their preparation and use |
JPS58157788A (en) * | 1982-03-16 | 1983-09-19 | Sankyo Co Ltd | Preparation of beta-lactam compound |
JPS5913757A (en) * | 1982-07-14 | 1984-01-24 | Sankyo Co Ltd | 3-mercaptopyprolidine derivative and its preparation |
JPS5916892A (en) * | 1982-07-19 | 1984-01-28 | Sankyo Co Ltd | Carbapenem-3-carboxylic acid derivative and its preparation |
CA1283906C (en) * | 1983-05-09 | 1991-05-07 | Makoto Sunagawa | .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF |
JPS60202886A (en) * | 1984-03-27 | 1985-10-14 | Sankyo Co Ltd | 1-substituted carbapenem-3-carboxylic acid derivative and its preparation |
DE3579888D1 (en) * | 1984-11-08 | 1990-10-31 | Sumitomo Pharma | CARBAPENE COMPOUNDS AND THEIR PRODUCTION. |
US4806637A (en) * | 1986-03-17 | 1989-02-21 | Schering Corporation | 6-(Hydroxyethyl)-2-(heterocyclylthio)-penem-3-carboxylates |
IE60588B1 (en) * | 1986-07-30 | 1994-07-27 | Sumitomo Pharma | Carbapenem compound in crystalline form, and its production and use |
-
1984
- 1984-05-03 CA CA000453478A patent/CA1283906C/en not_active Expired - Lifetime
- 1984-05-09 AT AT84303128T patent/ATE121402T1/en active
- 1984-05-09 ES ES532741A patent/ES8600305A1/en not_active Expired
- 1984-05-09 DE DE3486382T patent/DE3486382T2/en not_active Expired - Lifetime
- 1984-05-09 EP EP84303128A patent/EP0126587B1/en not_active Expired - Lifetime
-
1987
- 1987-10-08 US US07/106,036 patent/US4943569A/en not_active Expired - Lifetime
- 1987-10-08 US US07/106,035 patent/US4933333A/en not_active Expired - Fee Related
-
1990
- 1990-05-21 US US07/525,817 patent/US5122604A/en not_active Expired - Lifetime
-
1992
- 1992-06-19 MX MX9203063A patent/MX9203063A/en unknown
-
1995
- 1995-09-12 NL NL950019C patent/NL950019I2/en unknown
- 1995-11-30 HK HK183095A patent/HK183095A/en not_active IP Right Cessation
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2266590A2 (en) | 2002-02-22 | 2010-12-29 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
EP2316468A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
EP2316469A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
CN101711251B (en) * | 2007-06-26 | 2011-12-28 | 山东轩竹医药科技有限公司 | 1beta-methylcarbapenem antibiotics,the pharmaceutical composition and use thereof |
WO2017158616A1 (en) | 2016-03-16 | 2017-09-21 | Orchid Pharma Ltd. | Carbapenem compounds |
US11180504B2 (en) | 2016-03-16 | 2021-11-23 | Orchid Pharma Ltd. | Substituted carbapenems for the treatment of bacterial infections |
Also Published As
Publication number | Publication date |
---|---|
NL950019I1 (en) | 1995-11-01 |
HK183095A (en) | 1995-12-08 |
NL950019I2 (en) | 1997-03-03 |
ES532741A0 (en) | 1985-10-16 |
CA1283906C (en) | 1991-05-07 |
DE3486382T2 (en) | 1995-08-17 |
US4943569A (en) | 1990-07-24 |
MX9203063A (en) | 1992-07-01 |
US5122604A (en) | 1992-06-16 |
US4933333A (en) | 1990-06-12 |
EP0126587A1 (en) | 1984-11-28 |
ES8600305A1 (en) | 1985-10-16 |
DE3486382D1 (en) | 1995-05-24 |
ATE121402T1 (en) | 1995-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0126587B1 (en) | Carboxylic thio-pyrrolidinyl beta-lactam compounds and production thereof | |
EP0182213B1 (en) | Carbapenem compounds and production thereof | |
EP0243686B1 (en) | Beta-lactam compounds, and their production | |
US4925838A (en) | 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds | |
EP0070204B1 (en) | Carboxylic beta-lactam compounds and the preparation thereof | |
US4923857A (en) | 3-Alkenyl-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds | |
AU636913B2 (en) | Tricyclic carbapenem compounds | |
AU599439B2 (en) | 3-pyrrolidinylthio-1-azabicyclo (3.2.0)hept-2-ene-2-carboxylic acid compounds and processes for the preparation thereof | |
EP0188816B1 (en) | Novel beta-lactams and their production | |
HU196800B (en) | Process for producing carbepeneme derivatives and pharmaceutical compositions containing them as active component | |
EP0037080B1 (en) | 4-(3-carboxy-2-oxopropyl)-azetidino-2-ones and process for their preparation | |
JPH0463878B2 (en) | ||
KR900006449B1 (en) | Process for the preparation of azetidinone derivatives | |
JPH05279367A (en) | Production of beta-lactam derivative | |
EP0442497B1 (en) | Novel beta-lactam compounds and their production | |
JPS6355514B2 (en) | ||
JPS615081A (en) | Preparation of 1-substituted carbapenem-3-carboxylic acid derivative | |
IE58892B1 (en) | Carbapenem derivatives | |
CA2111974C (en) | Carbapenem derivatives | |
JPH0463076B2 (en) | ||
JPS6019764A (en) | Production of azetidinone derivative | |
US4369187A (en) | 3-Substituted-1-azabicyclo[3.2.0]hept-2-en-7-one-2-carboxylic acid | |
JP3242677B2 (en) | Novel β-lactam compound and method for producing the same | |
JPH0466872B2 (en) | ||
JP3005045B2 (en) | Novel β-lactam compound and method for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI NL SE |
|
17P | Request for examination filed |
Effective date: 19850520 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SUMITOMO PHARMACEUTICALS COMPANY, LIMITED |
|
17Q | First examination report despatched |
Effective date: 19890209 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE FR GB IT LI NL SE |
|
REF | Corresponds to: |
Ref document number: 121402 Country of ref document: AT Date of ref document: 19950515 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 3486382 Country of ref document: DE Date of ref document: 19950524 |
|
ITF | It: translation for a ep patent filed |
Owner name: SOCIETA' ITALIANA BREVETTI S.P.A. |
|
ET | Fr: translation filed | ||
MEDD | It: supplementary protection certificate for pharmaceutical products: granted |
Free format text: CCP 507, 19950918; SUMITOMO PHARMACEUTICALS COMPANY, L TD |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: SPCF Free format text: 9590016, 950127 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 121402 Country of ref document: AT Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: AC1 Free format text: NLAC1 950019, 950912 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: CTFF Free format text: GBCTFFSPC/GB95/030, 951006 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: CTFG Free format text: GBCTFGSPC/GB95/030, 960131, EXPIRES:20090508 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCF Free format text: CHSPCFIKS 53105/951228, 960320 |
|
CCPV | Be: grant of a complementary protection certificate |
Free format text: 096C0023, EXPIRES:20090509 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: SPCG Free format text: 9590016, 950127, EXPIRES: 20090509 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: AC1 Free format text: NLAC1 111111, 950912 Ref country code: NL Ref legal event code: KC1 Free format text: NLKC1 950019, 20040509, EXPIRES: 20090508 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CP Free format text: PRODUCT NAME: MEROPENEME; NAT. REGISTRATION NO/DATE: NL 20267 19970416; FIRST REGISTRATION: IT - 99/1994 19940817 Spc suppl protection certif: 97C0032 Filing date: 19970710 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CA |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCG Free format text: OICM 53105/19951228, 19960320, EXPIRES:20090508 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CR Free format text: FRCR 97C0032, 970710 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CY Free format text: FRCY 97C0032, 970710 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: EEZF Spc suppl protection certif: SZ 19/1995 Filing date: 19951010 Extension date: 20090509 Effective date: 19990810 Ref country code: AT Ref legal event code: ESZA Free format text: PRODUCT NAME: MEROPENEM Spc suppl protection certif: SZ 19/1995 Filing date: 19951010 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20030507 Year of fee payment: 20 Ref country code: GB Payment date: 20030507 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20030508 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20030514 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20030516 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20030522 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20030530 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20030725 Year of fee payment: 20 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20040508 Ref country code: CH Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20040508 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20040508 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20040509 Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20040509 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
BE20 | Be: patent expired |
Owner name: *SUMITOMO PHARMACEUTICALS CY LTD Effective date: 20040509 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Ref country code: GB Ref legal event code: CTFE Free format text: SPC/GB95/030: 20040509, EXPIRES: 20090508 Spc suppl protection certif: SPC/GB95/030 Filing date: 20040509 Expiry date: 20090508 |
|
EUG | Se: european patent has lapsed | ||
NLV7 | Nl: ceased due to reaching the maximum lifetime of a patent |
Effective date: 20040509 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: EELA Ref document number: 121402 Country of ref document: AT Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCM Owner name: DAINIPPON PHARMACEUTICAL CO., LTD., JP Free format text: FORMER OWNER: SUMITOMO PHARMACEUTICALS COMPANY, LIMITED, JP Spc suppl protection certif: C00126587/01 Ref country code: CH Ref legal event code: SPCP Owner name: DAINIPPON SUMITOMO PHARMA CO., LTD., JP Free format text: FORMER OWNER: DAINIPPON PHARMACEUTICAL CO., LTD., JP Spc suppl protection certif: C00126587/01 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: SPCT Spc suppl protection certif: 950019 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP Spc suppl protection certif: 97C0032 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCN Spc suppl protection certif: C00126587/01 Representative=s name: BOVARD AG PATENTANWAELTE, CH |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: CCCH Owner name: DAINIPPON PHARMACEUTICAL CO. LTD; JP Spc suppl protection certif: 96C0023 Filing date: 19960702 Effective date: 20060314 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCL Spc suppl protection certif: C00126587/01 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: CCRE Free format text: PRODUCT NAME: MEROPENEM TRIHYDR; NAT. REGISTRATION NO/DATE: 624 IS 88 F 12 19960205; FIRST REGISTRATION: IT 028949028 19940817 Spc suppl protection certif: 96C0023 Filing date: 19961008 Expiry date: 20040509 Extension date: 20090509 Effective date: 20090509 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: SPCE Free format text: PRODUCT NAME: MEROPENEM OPTIONALLY IN THE FORM OF A HYDRATE AND /OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: IT 99/1994 19940817; UK 12619/0097 19950119; UK 12619/0098 19950119; UK 12619/0099 19950119; UK 12619/0100 19950119 Spc suppl protection certif: SPC/GB95/030 Filing date: 19951006 Expiry date: 20040509 Extension date: 20090508 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCN Free format text: VERTRETERLOESCHUNG Spc suppl protection certif: C00126587/01 |